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ABSTRACT
Hall, Brian, Ph.D., May 2008

Pharmacology/Pharmaceutical Sciences

Structure Activity Relationships for Intracellular Loop 2 of the 5HT1A Serotonin
Receptor
Chairperson: Dr. Keith Parker
The human (H) serotonin (5-hydroxytrptamine; 5HT) 1a receptor (R) has been
implicated in various physiological processes such as mood regulation, vascular and
temperature control, anxiety, depression, and migraine headache. This seven
transmembrane domain (7TMD), G protein-coupled receptor (GPCR) is negatively
coupled to adenylyl cyclase (AC). This work was designed to better understand the
coupling and activation requirements of intracellular loop 2 (ic2) with Gi in Chinese
Hamster Ovary (CHO) cells. 10 MER peptides that are derived from the known sequence
of the cloned receptor have been used as probes and the current study includes peptides
P21 to P27 of ic2 (LDRYWAITDPIDYVNKRTPRPR), approaching the ic2 carboxy
terminus of TMD4 two residues per 10 MER. Peptide ability to uncouple receptor from
G protein was determined in agonist inhibition studies using the selective 5HT1aR
agonist [3H]8-OH-DPAT. Peptides P21 to P23 uncoupled the G protein from the receptor
to 50% of control. Peptides P24 to P27 uncoupled the G protein from the receptor to 615% of control. Peptide capacity to alter signal transduction was measured using
enzyme-linked assays of intracellular cyclic AMP (cAMP) and assays quantifying
incorporation of [35S]-γ-Guanosine Triphosphate (GTP). Peptides closer to TMD3, but in
the C-terminal aspect of ic2, were capable of uncoupling the receptor-G protein,
suggesting a role for that region of the native receptor in G protein coupling (and
activation). The final peptides in this region, P25 to P27 are relatively inactive with
respect to G protein coupling and activation. Thus, we propose that the immediate
ic2/TMD4 interface is beyond the receptor segment involved in coupling. Peptides P22P24 were the most active with respect to stimulation of [35S]-γ-GTP incorporation and
decreasing cAMP concentration, therefore they were chosen for a thermodynamic
binding study. The Kd for [3H]8-OH-DPAT was measured over a range of temperatures,
which allowed the calculation of Standard Gibb’s Free energy (ΔG°), enthalpy (ΔH°),
and entropy (ΔS°). The peptides increased the enthalpy and entropy of the system. These
results contribute to structural information about 5HT1aR's interaction with Gi derived
from a number of different, but compatible techniques. The developing model for ic2
(and ic3) loop-G protein regulation has implications for developing new therapeutic
drugs for serotonergic pathologies such as the affective disorders.
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SEROTONIN INTRODUCTION
The molecule, serotonin (5-HT, 5-hydroxytryptamine), was discovered after its
effect on vasoconstriction and platelet aggregation during the clotting process was noted
(Raymond et al., 1999; De Clerck, 1990). Since that time, it has been shown that
serotonin has important roles in multiple biological systems as a neurotransmitter and a
paracrine autacoid factor. Serotonergic dysfunction has been implicated in multiple
disease states for which treatments have been developed including depression, obsessivecompulsive disorder, migraine headache, and emesis (Cowen, 2000; Pietrobon, 2003;
Mann, 2005; Feeney et al., 2007). Reserpine and ergot alkaloids were two of the first
agents, which were used clinically. Reserpine was used as an antihypertensive agent,
which worked by depletion of the monoamine neurotransmitters (noradrenaline,
dopamine, serotonin). Depression was a notable side effect, however, due to the decrease
in serotonin levels in the central nervous system (CNS) (Webster et al., 1996). The ergot
derivatives, ergotamine and ergonovine, are potent vasoconstrictors used for treating
vascular headaches (migraine) and post-partum hemorrhage (McCarthy et al., 1989;
Mousa et al., 2007). The involvement of these therapeutic agents in modulating
serotonergic transmission was only discovered long after they had been in use. Their
efficacy provides clinical evidence of their mechanism of action.
Serotonin is synthesized in a two-step process that begins with the amino acid Ltryptophan. The first, and rate-limiting, step in the conversion is the hydroxylation of Ltryptophan by tryptophan hydroxylase (TPH), followed by the decarboxylation of L-5hydroxytryptophan by L-aromatic amino acid decarboxylase. The serotonin molecule
can then be metabolized in two ways. It can be converted in a two-step process to
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melatonin or oxidized by monoamine oxidase (MAO B) with final enzymatic conversion
to 5-hydroxyindoleacetic acid (5-HIAA) or 5-hydroxy-tryptophol (Sanders-Bush et al.,
2001).
Metabolism of serotonin does not occur in the neuronal synapse; rather it involves
the serotonin reuptake transporter (SERT) that clears serotonin from the synapse from
which it is either recycled by storage in vesicles or fed into the metabolic pathway. The
development of selective SERT inhibitors (fluoxetine, paroxetine, citalopram,
escitalopram) led to a revolution in the treatment of major depressive disorder, obsessive
compulsive disorder, and panic disorder with fewer side effects than the monoamine
oxidase inhibitors (MAOI) and tricyclic antidepressants (TCA) (Taylor et al., 2006).
Following the initial discovery of the serotonin molecule, it was recognized that a
receptor protein mediated its actions. Using pharmacological binding assays with [3H]-5HT the specific tissues in which the receptor are expressed were identified (central
nervous system, vascular smooth muscle, gastrointestinal tract). However, it soon
became apparent by their differing binding affinities for [3H]-5-HT that a homogeneous
serotonin receptor population did not exist across all tissues. The development of
specific agonist and antagonist ligands (8-OH-DPAT, sumatriptan, ketanserin) was the
first means available to classify the receptors into distinct subgroups (Hoyer et al., 1994;
Peroutka, 1994; Barnes et al., 1999; Schnellmann, 1984).
cDNA cloning and other molecular biology techniques have allowed for a more
robust classification system based upon the primary structure of the individual receptor
proteins. It has also led to the discovery of new receptor subtypes. There are currently
seven recognized families of 5-HT receptors, which include a number of structurally and

2

pharmacologically distinct receptor subtypes, for a total of 14 known receptors. All of
the receptors are 7 transmembrane domain (7TMD) G protein-coupled receptors
(GPCRs), except the 5-HT3 receptor family, which is a ligand-gated ion channel. The 5HT3 receptor is structurally related to other ligand gated ion channels such as the
nicotinic acetylcholine receptor, GABAA receptor, and the glycine receptor, all of which
use a disulfide bond (Cys-Cys) to form a gating loop for their respective ion channels
(Barnes, 1999).
The linear polypeptide of the seven transmembrane domain receptors passes
through the cell membrane in a serpentine fashion seven times (See Figure 1 for example;
5HT1a receptor). The peptide’s amino terminus is extracellular and the carboxy terminus
is usually intracellular, although it can be inserted into the cell membrane. This creates
three distinct regions, which are able to influence the protein’s secondary and tertiary
structure. These regions are the extracellular loops, which are important for ligand
binding, the transmembrane domains, which are important for tertiary structure, and the
intracellular loops that are important for coupling to and activation of the G protein
(Raymond et al., 1999; Baldwin 1994).
G proteins are heterotrimeric guanosine diphosphate (GDP) binding proteins
consisting of α, β, and γ subunits. The _ and γ subunits are tightly linked to each other to
form a dimer. The signal transduction system that is modified by the activation of the
receptor and G protein coupled to it depends on its α subunit. The Gα subunit is
responsible for binding to GDP and guanosine triphosphate (GTP). The 3 most common
Gα subunits are Gαs, Gαi, Gαq. All Gα subunits possess GTPase activity; this means they
are able to catalyze the hydrolysis of the γ phosphodiester bond of GTP yielding GDP
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and phosphate (Pi). Gαs activation results in increased intracellular cAMP concentrations
and protein kinase A (PKA) activity. Gαi activation results in decreased intracellular
cAMP concentrations and PKA activity. Gαq activation results in increased inositol
triphosphate (IP3) and diacylglycerol (DAG) concentrations as well as increased protein
kinase C (PKC) activity. The Gβγ subunits are regulators of ion conductance into the cell
(Gilman, 1987; Stryer, 1986; Dolphin, 2003).

Figure 1: Schematic of Human 5HT1a Receptor
A representation of the human 5HT1a receptor protein. From Raymond et al.,
1999. Intracellular loop (ic) 2 and 3, shown below the gray cell membrane, are
the focus of the following studies. See also Figure 35.
4

G protein activity is regulated by the guanine nucleotide exchange factors (GEF)
family and GTPase activating proteins (GAP) family. GEFs act to promote the exchange
of GDP for GTP, which activates the G protein. GAPs increase the rate of hydrolysis of
GTP by Gα, which deactivates the G protein (Narumiya, 1996).
Ligand binding to a G protein-coupled receptor is influenced by the receptor’s
affinity state (in this case 5-HT or 8-OH-DPAT to 5-HT1A receptor). The affinity state is
referred to as a high affinity or low affinity ligand binding state (Figure 2). The high
affinity ligand binding state occurs when the receptor protein has the G protein bound to
(coupled) to its intracellular loops. In this state the most robust binding interaction of the
ligand or agonist can occur, activating the G protein mediated signal transduction
cascade. The low affinity ligand binding state occurs when the receptor protein does not
have the G protein bound to (coupled) its intracellular loops. The ligand or agonist is still
able to bind to the receptor in this state, but the interaction is less robust, and it is not
possible to activate the G protein mediated signal transduction cascade (Maguire et al.,
1976; Peroutka et al., 1979).
The sequence of events from ligand receptor binding to activation of the signal
transduction cascade is dependent on all of the players being in the right place at the right
time. The sequence begins with a ligand finding a receptor coupled to its G protein
(which has GDP bound in its Gα subunit), thus in its high affinity state. The ligand binds
to the receptor-G protein complex, which induces a conformational change in the
receptor protein. This change in shape is transmitted to the G protein, which causes a
conformational change in the Gαβγ subunits. The change in the Gα subunit is of particular
interest because it lowers the protein’s affinity for the GDP, which up until now has been
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bound in its active site. With the Gα active site now unoccupied, it is available to bind a
GTP molecule. The GTP- Gα interaction induces another conformational change leading
to the dissociation of Gα from Gβγ. The freed Gα subunit can then, depending on its type
(Gαs, Gαi, Gαq), influence changes in its second messenger system (cAMP, IP3 and DAG)
and activate various protein kinases. The freed Gβγ subunit can now interact with ion
channels and increase the conductance of ions into the cell affecting the cell’s electrical
membrane potential (Stryer 1986, Dolphin 2003).
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Figure 2: 5HT1a Receptor High
Affinity Ligand Binding
The 5HT1aR is in its low
affinity ligand binding state
when it is not coupled to the G
protein (Gi)

When 5HT1aR is coupled to G
protein (Gi), the receptor is in
its high affinity ligand binding
state

The binding of the 5HT1a ligand
8-OH-DPAT is most efficient
when the receptor is in its high
affinity ligand binding state
(coupled to G protein)
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The signal transduction cascade is a complex process involving multiple proteins
and cofactors. The complexity of this cascade presents multiple points for possible
pathology, and opportunities for intervention. There are two ways in which the system
can be changed, mutations in the receptor protein or mutations in the G proteins, to which
they couple. Mutations in receptor proteins have been identified as the cause of several
diseases. X-linked nephrogenic diabetes insipidus is caused by mutations in the arginine
vasopressin receptor (V2); its ligand arginine vasopressin is also known as antidiuretic
hormone. This receptor mutation disables the kidneys’ ability to reabsorb water in the
nephron, causing excessive water loss and low urine osmolality (dilute). An example of
disease caused by G protein dysfunction due to a mutation in the Gαs subunit, which
inactivates it, is associated with pseudohypoparathyroidism. Pseudohypoparathyroidism
leads to the development of resistance to the glycoprotein hormones thyroid stimulating
hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), and
parathyroid hormone (PTH). TSH resistance leads to symptoms of hypothyroidism (loss
of hair, bradycardia, hypothermia), LH and FSH resistance leads to reproductive
problems, and PTH resistance leads to the loss of calcium homeostasis in the body
(Schoneberg et al., 2004; Spiegel et al., 2003).
A group looking for more receptor subtypes in the β-adrenergic receptor family
first cloned the 5-HT1A receptor from an intronless gene product and is 422 amino acids
in length (Fargin et al., 1988). The peptide’s carboxy terminus re-inserts into the
membrane creating a 4th intracellular loop via palmitoylation at cysteine residues
(Raymond et al., 1999). The similar homology between these receptors is evident by the
ability of selected β-adrenergic ligands (pindolol, propranolol) to also act as ligands at the

8

5-HT1A receptor (Kuipers et al., 1997; Sprouse et al., 1986), which was found to be due to
the conservation of the Asn 385 in the 7th transmembrane domain of both receptors (Guan
et al., 1992). This was discovered by the generation of receptor clones with point
mutations of one amino acid at a time. The 5-HT1A receptor is found in neural tissue of
the central nervous system at highest concentrations in the hippocampus, septum, frontal
cortex, and dorsal raphe nucleus (Lanfumey et al., 2000).
Following the activation of the 5-HT1A receptor in the hippocampus, septum, and
frontal cortex by 5-HT or other agonists, the receptor associated neurons are
hyperpolarized. In these regions the receptor is found post-synaptically and on
serotonergic neuron terminals pre-synaptically. The activation of the receptors in the
dorsal raphe nucleus by 5-HT also results in the hyperpolarization of neurons. However,
it has the added effect of decreasing the release of 5-HT in the forebrain region. This is
likely due to the actions of the 5-HT1A autoreceptor (Price et al., 1996). The affect of 5HT on the release of other neurotransmitters has also been noted. It has been shown that
post-synaptic 5-HT1A receptors increase the release of acetylcholine in the cortex and
hippocampus. The release of noradrenaline is increased in the hypothalamus,
hippocampus, frontal cortex, and ventral tegmental area following activation of the 5HT1A receptor. The physiological and behavioral actions mediated by the 5-HT1A
receptor include hyperphagia, hypothermia, alterations in sexual behavior, and clinical
use of 5-HT agonists as anxiolytics and antidepressants (Barnes et al., 1999).
The human 5-HT1A receptor is negatively coupled to adenylyl cyclase (AC) by the
Gi protein (Raymond et al., 1992; Fargin et al., 1989). There are 8 isoforms identified for
adenylyl cyclase (AC1-AC8). The isoforms are differentially expressed in many tissues,
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AC1 and AC8 expressed in neural tissue and AC5 in heart and brain. The isoforms AC1,
AC3, AC5 and AC6 are sensitive to inhibition by Gαi. This selectivity is due to the posttranslational N-terminal fatty acylation of Gαi protein. All known AC isoforms are
stimulated to produce cAMP by the diterpine natural product forskolin (FSK) (Simonds,
1999).
The AC enzyme is embedded in the cell membrane which the protein spans 12
times. AC has two catalytic subunits lying along the inside of the cell membrane
(Simonds, 1999). Upon stimulation of AC by Gαs, the catalytic subunits transform
adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). AC cleaves
the two terminal phosphates (PPi) off ATP by a nucleophilic attack of the 3’ ribose
hydroxyl oxygen on the α phosphate creating cAMP and PPi. The activity of the
catalytic subunits is regulated by interactions with Gαs and Gαi (Sinha et al., 2006).
cAMP is converted to adenosine monophosphate (AMP) by the phosphodiesterase
enzyme subtype, inactivating it as a second messenger signaling molecule (Omori et al.,
2007).
The 5-HT1A receptor selectivity couples to the Gi protein; it has been shown that
this is due to palmitoylation of cysteine residues near the carboxy terminus (Raymond et
al., 1999). Activation of the 5-HT1A receptor causes the intracellular levels of cyclic
adenosine monophosphate (cAMP) to fall. The decreased cAMP production by AC is
due to the interaction with the G-protein subunit Gαi. It is also able to hyperpolarize
neurons by opening voltage gated calcium channels (N- and P/Q-types). These channels
are opened upon interaction with Gβγ subunit (Dolphin, 2003).
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Understanding the relationship between the receptor protein and its G protein is
important to elucidating the mechanism of signal transduction. Which parts of the
receptor’s intracellular loops are important for coupling to the G protein? Which are
important for activation of the G protein? One method of assessing this is the use of
peptide mimics of the receptor of interest’s intracellular loops. Peptidomimetics (varying
in amino acid length of the intracellular loops) have been used to examine G protein
coupling and activation in α2A adrenergic, β2 adrenergic, and δ opioid receptor systems
(Taylor et al., 1994; Munch et al., 1991; Merkouris et al., 1996).
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EXPERIMENTAL METHODS
Cell Culture
Chinese hamster ovarian (CHO) cells expressing the human 5HT1aR were
cultured in Ham’s F-12 medium fortified with 10% fetal calf serum and 200 µg/ml
geneticin in 75 or 175 cm2 flasks. Cultures were maintained at 37 °C in a humidified
atmosphere of 5% CO2. Cells were subcultured or assayed upon confluency (5–8 days).
CHO cells with cloned human 5HT1aR was kindly provided by Dr. John Raymond
(Medical University of South Carolina). NIH 3T3 cells expressing the rat 5-HT2aR were
cultured under similar conditions in DMEM fortified with 10% calf serum and 200 µg/ml
geneticin. These transfected cells were generously provided by Dr. David Julius (UCSF).
Both cell lines have been tested for mycoplasma with a PCR kit (ATCC), and are free of
contamination.

Receptor Preparation
Cells were harvested by the removal of culture medium followed by the addition
of a 0.25% trypsin solution. Upon the removal of the cell monolayer, an equal volume of
ice-cold culture medium was added to the cell-trypsin solution. The resulting cell
suspension was centrifuged at low speed (3000 rpm) in ice-cold medium for 10 minutes.
The pellet was re-suspended in ice-cold Earle’s balanced salt solution followed by
centrifugation (3000 rpm) for 10 minutes. The cell pellet was re-suspended in 10 ml of
ice-cold binding buffer (50 mmol/l Tris, 4 mmol/l CaCl2, 10 µmol/l pargyline, pH 7.4),
homogenized with Teflon-glass homogenizer, and centrifuged at 450,000 g at 4 ° C. To
produce a crude membrane preparation, the pellet was re-suspended in 30 ml of ice-cold
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binding buffer, and homogenized, first with Teflon-glass then with a Polytron (setting 4)
for 5 seconds. The receptor preparation was stored on ice and assayed within the next 1.5
hour.
Assay of Receptor Activity
Binding of the agonist [3H]8-OH-DPAT ([3H]8-hydroxy-2-(di-npropylaminotetralin)) to H5-HT1aR followed well-characterized in vitro protocols
(Thiagaraj et al., 2007). Radioligands were purchased from New England Nuclear
(Boston, Mass., USA). The experimental 1 ml reaction mixtures, in triplicate, were
incubated for 30 minutes in a 30 °C water shaker bath. The composition of the 1 ml
reaction mixture was:
Experimental controls: 700 µl of receptor preparation; 100 µl of either binding buffer
(for total ligand binding) or 10 µM 5HT (final concentration for non-specific ligand
binding), 100 µl of the tritiated agent (final concentration of 0.5 nmol/l [3H]8-OHDPAT), and 100 µl of binding buffer in the case of controls.
DPT (dipropyltryptamine) Experiments: 700 µl of receptor preparation; 100 µl of either
binding buffer (for total ligand binding) or 10 µmol/l 5-HT (final concentration for nonspecific ligand binding), 100 µl of the tritiated agent (final concentration of 0.5 nmol/l
[3H]8-OH-DPAT), and 100 µl diluted DPT (dipropyltryptamine). In the case of
experiments that varied in both DPT concentration and [3 H]8-OH-DPAT concentration,
the following radioligand concentrations were used: 0.2, 0.4, 0.6, 0.8, and 1.0 nmol/l.
Reactions were stopped by addition of 4 ml of ice-cold 50 mmol/l Tris buffer, pH 7.4,
and subsequent vacuum filtration on glass fiber filters (Whatman GF/B). Filters were
rinsed twice in 5 ml of ice-cold Tris buffer, dried, and counted in 5 ml of Ecoscint
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(National Diagnostics) liquid scintillation fluid in a Beckman LS 6500 instrument.
Homogenates were assayed for protein (Bradford, 1976) to maintain a nominal value of
50 µg protein per filter over weekly assays. Total and non-specific binding tubes were
run in triplicate.
Peptide Experiments: 700 µl of receptor preparation; 100 µl of either binding buffer (for
total ligand binding) or 10 µmol/l 5-HT (final concentration for non-specific ligand
binding), 100 µl of the tritiated agent (final concentration of 0.5 nmol/l [3H]8-OHDPAT), and 100 µl diluted peptide (30 µmol/l). Reactions were stopped and data was
gathered as in the DPT experiments above.
cAMP Assay
These experiments were a measure of Giα regulatory effects on adenylyl cyclase.
CHO cells were cultured to confluency in 12- or 24-well plates. Culture medium was
aspirated and the cells were rinsed twice in warm serum-free F-12 medium. Cells were
then incubated for 20 min at 37 °C in 0.5 ml of serum-free F-12 medium containing 100
µmol/l isobutylmethylxanthine (IBMX) and the following substances (final
concentrations) alone or in combination: 30 µmol/l forskolin (FSK)(for all treatments);
1–10 µmol/l 5-HT; 0.1–1 µmol/l DPT or peptide (30 µmol/l). Reactions were stopped by
aspiration of medium and addition of 0.5 ml of 100 mmol/l HCl. Following a 10 minute
incubation, well contents were removed and centrifuged at 4,000 rpm. The pellets were
discarded and the resulting supernatants were diluted in 100 mmol/l HCl, and cAMP was
quantified (Thiagaraj et al., 2007) directly in a microplate format by colorimetric enzyme
immunoassay using a kit from Assay Designs (Ann Arbor, Mich., USA). Triplicate
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independent samples at a minimum were assayed in quadruplicate, yielding an n of 12 for
each tested condition.
γ-S-GTP Incorporation
These experiments were a measure of the activation of the G protein (Thiagaraj et
al., 2005). H5-HT1aR membranes from transfected CHO cells were incubated with 5-HT
(0.1 µmol/l) and/or DPT (0.1–1,000 µmol/l) or peptide (30 µmol/l), and the following
incubation mixture: 20 mmol/l Hepes buffer, pH 7.4(5 mmol/l MgCl 2 , 1 mmol/l EDTA,
1 mmol/l DTT, 100 mmol/l NaCl, 100 µmol/l GDP, 10 µmol/l pargyline, 0.2 mmol/l
ascorbate, and 0.1 nmol/l [35S]-γ-S-GTP. The mixtures were incubated for 30 min at 30
°C, and were terminated by dilution in ice-cold buffer. The reaction mixture was filtered
on GF/C filters, and rinsed twice in ice-cold buffer, followed by drying and liquid
scintillation counting. The negative control (basal incorporation of GTP) was the above
mixture minus DPT or peptide or 5-HT. The non-specific binding was determined in the
presence of cold γ-S-GTP (10 µmol/l). Positive control was H5-HT1aR membranes in the
same incubation mixture plus 5-HT. The calculation for specific binding = total binding –
non-specific binding; all experimental conditions were run in triplicate.
Studies of concentration-dependent inhibition of [3H]8-OH-DPAT binding
Concentration-dependency was studied as described for agonist binding assays in
membrane bound preparations, except that [3H]8-OH-DPAT concentrations
were varied in five steps from 0.2 to 1.0 nmol/l, through the Kd of about 0.6 nmol/l.
Peptide concentrations were chosen based upon preliminary information gained from
inhibition studies at fixed agonist concentration.
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Peptide Preparation
The peptides were purchased from New England Peptide LLC. These peptides are
segments of intracellular loops 2 and 3 of the cloned H5HT1aR. Peptides stored at -20°
C were initially dissolved in de-ionized water. Subsequent dilutions of peptides were in
binding buffer.
Thermodynamic Drug-Receptor Binding Assays
Homogenate preparation and binding of the agonist [3H]8-OH-DPAT ([3H]8hydroxy-2-(di-n-propylamino)tetralin) to receptors was performed as above. Assays run
in triplicate were incubated in a shaker water bath (except for 0° C; ice; 1 hr.) for the
following temperature/time combinations: 35° C/15 min.; 30° C/30 min.; 25° C/30 min.;
15° C/45 min. (McGonigle and Molinoff, 1989). Each reaction mixture consisted of 700
µl receptor preparation, 100 µl binding buffer (total binding) or 10 µM 5HT in binding
buffer (non-specific binding), 100 µl 0.4, 0.6, 0.8, 1.0, or 2.0 nM [3H]8-OH-DPAT, and
100 µl experimental displacing agent (peptide or 100 µl of binding buffer for nondisplacement reactions), yielding a total volume of 1 ml. Incubations were terminated
with 4 ml ice-cold Tris buffer and rapid filtration over Whatman GF/B glass fiber filters.
Two successive ice-cold 5 ml Tris buffer rinses followed. The dried filters were counted
in 5 ml of Ecoscint liquid scintillation fluid (National Diagnostics; Atlanta) in a Beckman
LS 6500 system.
Thermodynamic Calculations
Saturation binding analysis was performed for [3H]8-OH-DPAT at the H5HT1aR.
The following concentrations were used: 0.4, 0.6, 0.8, 1.0 and 2.0 nM. Total and nonspecific binding was determined in triplicate, in at least two independent experiments.
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Complete experiments were performed at the following Centigrade temperatures: 0, 15,
25, 30, and 35. The same sequence of experiments were conducted in the presence of the
following substances: P11 (8 µM), P21-P27, and DPT (40 nM). Using reciprocal analysis
(Scatchard or a Lineweaver-Burk type double inversion), the Kd’s were calculated for
[3H]8-OH-DPAT in every case (Hall et al., 2008). Graphing the inverse Kd versus
reciprocal absolute temperature produces a Van’t Hoff plot. The slope of this relationship
is then used to calculate the standard enthalpy (H°). The standard Gibb’s Free Energy
(G°) was determined from each Kd at 25°C using an Arrhenius-like calculation: ∆G° = RT ln(1/Kd). Having the standard enthalpy and standard free energy, allowed
determination of the standard entropy (S°) from the Gibb’s Free Energy Equation (∆G =
∆H–T∆S).
Data Analysis
All statistics (means, standard errors of the mean (SEM), t tests and ANOVA,
Pearson correlation coefficients(r), and graphical procedures (including drug-receptor
binding analysis) in the study were conducted with PSI-Plot (Version 7) software (Poly
Software International), Prism (version 4.0c), or using a Hewlett-Packard Graphing
Calculator, HP48. The apriori α was 0.05 for all experiments, unless indicated otherwise.
Experiments were conducted with a minimum of three independent n, all assayed in
triplicate. Most experiments were n = 3-5, in triplicate. In some cases (indicated in figure
legends), different n’s and multiplicates were used.
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5HT1AR INTRACELLULAR LOOP 2 SIGNAL TRANSDUCTION
5HT1aR Intracellular Loop 2 Introduction
The second intracellular loop (ic2) of the H5HT1aR consists of 21 amino acids
between the membrane spanning TMD3 and TMD4. Previous studies have examined the
role of ic2 in coupling to the G protein. These studies found, using point amino acid
substitution, that Thr149 is necessary for receptor coupling to Gβγ. This study also found
that Tyr144 is most important for activation of the G protein subunits Giα and Gβγ
(Kushwaha et al., 2006).
To date there have been no diseases identified in humans which are related to
either point mutations or deletions in the 5HT1aR. There are, however, reports from
other members of the seven transmembrane domain G protein coupled receptor family
that mutations in ic2 cause changes in receptor agonist affinity. Studies have shown that
the ic2 DRY sequence is highly conserved in all members of the GPCR family. An
important point mutation in this sequence is reported in the human gonadotropin
releasing hormone (GnRH) receptor that has a serine substituted for the tyrosine (DRS).
Replacing the tyrosine in this receptor system showed a 100% increase in agonist binding
affinity and a 60% increase in the internalization of the receptor (Arora et al., 1999).
The peptide P11 (Table 1), which consists of the N-terminal side of ic2, was
tested previously in our laboratory for activity in H5HT1aR signal transduction (Figures
3, 4, 5). It was observed that as the concentration of P11 was increased, there was a
decrease in the coupling of the receptor to the G protein, as evidenced by a decrease in
the specific binding of [3H]-8-OH-DPAT (Figure 3). This decrease in high affinity ligand
binding is hypothesized to be due to P11 acting at the interface between 5HT1aR and G
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protein and uncoupling them. This shifts the receptor to its low affinity ligand binding
state, which accounts for the remaining [3H]-8-OH-DPAT bound to the receptor that was
measured in these experiments.
Further experiments were designed to measure the effect of P11 on the signal
transduction cascade. To measure the activation of G protein the incorporation of γ-[35S]GTP into Giα was measured. Giα is a negative regulator of adenylyl cyclase (AC). As a
secondary measure of G protein activation, the intracellular concentration of cAMP was
measured following AC stimulation with forskolin. These experiments revealed P11 was
not able to stimulate either the incorporation of γ-[35S]-GTP into Giα (figure 4) or
decrease the production of cAMP by adenylyl cyclase (data not shown) (Thiagaraj et al.,
2007). These data indicate that the portion of ic2 represented by P11 is important for
coupling the receptor to G protein, but has no role in G protein activation.
The thermodynamic effect of P11 on the binding of ligand to the receptor was
also measured. The observed trend for the Kd of [3H]-8-OH-DPAT was that temperature
and Kd are inversely related, as temperature increases the dissociation constant decreases.
The previous data for ic2 peptide P11 is shown; the Kd is the inverse of the x-intercept of
the regression line. The inverse of the y-intercept is the amount of drug specifically
bound to the receptor, which shows that more [3H]-8-OH-DPAT is bound to the receptor
at 35 °C (Figure 5). These data indicate that the entropy of the system drives agonist
binding to receptor; the peptide increases the entropy.
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Figure 3: P11 Agonist 8-OH-DPAT Binding Displacement
Displacement of specifically bound [3H]-8-OH-DPAT in membrane preparations of
H5HT1aR by the TM3/ic2 peptide probe P11. P11 concentrations are -log(mol/L).
P11 IC50 7±1 uM. Figure from Thiagaraj et al., 2007.
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Figure 4: P11 G Protein Activation Activity
[35S]-γ-GTP incorporation into H5HT1aR membranes by 5HT, and P11.
Results are mean ±S.E.M. of two experiments, all run in triplicate.
Values are expressed as percent of [35S]-γ-GTP incorporated in controls
(basal) lacking 5HT or P11. [35S]-γ-GTP concentration in all conditions is
0.1 nmol/l. 5HT concentration is 1 umol/l. P11 concentration is 0.1
mmol/l. Figure from Thiagaraj et al., 2007
Statistics:
P < 0.05 for 5HT vs. control, and 5HT/P11 vs. control. All other
comparisons are non-significant.
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Figure 5: P11 Changes Kd of 8-OH-DPAT at 25 °C and 35 °C
Inversion plots of [3H]8-OH-DPAT binding to membrane preparations of H5HT1aR in
the presence of ic2 peptide P11 (8 uM) at 25 °C and 35 °C. Kd is the inverse of the xintercept. The inverse of the y-intercept is the amount of drug specifically bound to
the receptor. Hall, 2008. r at 25°C = 0.98; r at 35°C = 1.00.
Regression lines are: 25°C y = 15.74x + 2.82; 35°C y = 6.85x + 2.82.
Peptide
Sequence

P11
P21
P22
P23
P24

IALDRYWAITD
LDRYWAITDP
RYWAITDPID
WAITDPIDYV
ITDPIDYVNK

P25

DPIDYVNKRT

P26

IDYVNKRTPR

P27

YVNKRTPRPR

Table 1: ic2 Peptide Mimics
The primary amino acid sequences for the H5HT1aR ic2 loop peptide mimics. The receptor’s
amino terminal is to the left. Sequences for H5HT1aR from Kobilka et al., 1987. P11 is from a
previous study by Thiagaraj et al., 2007. Peptides P21 to P27 were utilized to elucidate the role
of each segment of ic2 represented to couple receptor to G protein. The peptides’ subsequent
effect on the signal transduction cascade was also measured by G protein activation and second
messenger regulation.
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5HT1aR Intracellular Loop 2 Binding Results; HYPOTHESIS: Segments of loop 2 are
differentially involved in coupling and activation of Gi.
The introduction of the peptide mimics of ic2 (Table 1) had varying effects on the
specific binding of [3H]-8-OH-DPAT to H5HT1aR (Figures 6 &7, Table 2). The most
efficient uncouplers of the receptor and G protein, as evidenced by the decrease in
specifically bound agonist versus control are P21-P23. P21-P23 yield values of about
50% (as a percent of control which is 100%) inhibition of specifically bound agonist in
the 7-30 uM peptide concentration range. The IC50 values were calculated for these
peptides. The peptides P24-P27 were able to inhibit specific binding of agonist very
poorly (6-25% of control) at a 30uM peptide concentration. These peptides were such
poor uncouplers that the IC50 calculation could not be done. The IC50 data supported
the hypothesis by showing that as the peptides progressed from the amino terminus of ic2
towards its carboxy terminus they wane in importance for coupling the receptor to G
protein. The peptides closer to ic2 carboxy terminus could not decrease the ligand
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Figure 6: P21 Concentration Dependent Displacement of Bound 8-OH-DPAT
This curve represents the change in specific binding of [3H]-8-OH-DPAT, a 5HT1aR
agonist, to the receptor in the presence of various concentrations of the ic2 peptide
mimic P21. The curve shows that as the concentration of P21 is increased the
amount of agonist bound to the receptor decreases.
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Figure 7: Concentration Dependent Changes in 8-OH-DPAT Binding for P23 and P25
This graph shows the differential abilities of H5HT1aR ic2 peptide mimics P23 (lower
line, diamond shape) and P25 (upper line, square shape) to alter the specific binding of
[3H]-8-OH-DPAT as the peptide concentration increases.
Peptide
P11
P21
P22
P23

(7 uM)
(15 uM)
(16 uM)
(30 uM)

%Agonist Binding
50
52
50
51

Peptide % Agonist Binding
P24 (10 uM)
94
P25 (30 uM)
87
P26 (30 uM)
75
P27 (30 uM)
90

IC50
(uM)
7±1
15±4
16±2
30±22
SEM
9
12
19
5

Table 2: ic2 Peptide Mimic Effect on 8-OH-DPAT Binding
Cumulative agonist binding inhibition values are shown for all 5HT1aR ic2
peptide mimics. All values are percent of control, except the IC50 values,
which are concentration (uM). The upper portion of the table is the peptides,
including P11 from previous work by Thiagaraj et al., 2007. These peptides
decreased the specific high affinity binding of 5HT1aR agonist [3H]-8-OHDPAT by 50%. The lower portion of the table, are the ic2 peptides further
toward the loop’s carboxy terminus. These peptides were less effective at
decreasing specific high affinity binding of [3H]-8-OH-DPAT.
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5HT1aR Intracellular Loop 2 Thermodynamic Binding Results; HYPOTHESIS: The
binding of ligand to receptor is an entropically driven reaction.
The specific binding of the radioligand [3H]-8-OH-DPAT to 5HT1aR can be
measured at a range of temperatures, which allows for the calculation of various
thermodynamic binding parameters. The specific binding of [3H]-8-OH-DPAT was
calculated from binding assays which had reached equilibrium at the following times and
temperatures: 60 minutes at 0°C, 45 minutes at 15°C, 30 minutes at 25°C, 30 minutes at
30°C, and 30 minutes at 35°C. A dissociation constant, Kd, was calculated for each
temperature (Table 3). The Kd is the concentration of [3H]-8-OH-DPAT at which 50% of
the receptor ligand-binding sites are occupied. The observed trend for the Kd of [3H]-8OH-DPAT was that temperature and Kd are inversely related; as temperature increases,
the dissociation constant decreases. This is shown for P23 in a modified LineweaverBurke plot showing the difference in the specific binding of [3H]-8-OH-DPAT at 15 °C
(lower line) and 30 °C (upper line) (Figure 8). The Kd is the inverse of the x-intercept of
the regression line. The inverse of the y-intercept is the amount of drug specifically
bound to the receptor, which shows that more [3H]-8-OH-DPAT is bound to the receptor
at 30 °C.
The data for the changes in Kd for [3H]-8-OH-DPAT alone was previously
determined and are generally smaller than when the ic2 peptides are introduced into the
binding assay. The variability in the Kds for P22-P24 is explained by the decrease in
high affinity ligand binding caused by the peptides. With the receptor shifted to its low
affinity ligand binding conformation the concentration of ligand needed to reach the 50%
bound and unbound is increased. Interestingly the results for P23 show that the peptide is

24

not that different from the ligand alone, especially at increased temperatures. This
mirrors the previous data, which showed that the P23 region of ic2 affected the receptor’s
signal transduction pathway in a manner similar to agonist. It will also be shown that
P23 affected the thermodynamics of the system like the agonist, also yielding positive
entropy, supporting the hypothesis.
Temperature

0 °C
15 °C
(273 K) (288 K)

Compound
[3H]-8-OH-DPAT
(Alone)
P11 (8 uM)
P22
P23
P24

3.42
(0.42)
99.80
(16.57)
60.8
(5.2)
15.42
(1.02)
68.6
(23.4)

2.66
(0.12)
7.79
(0.27)
29.53
(2.5)
4.52
(0.61)
5.83
(0.88)

25 °C
30 °C
(298 K)
(303 K)
Kd (nM)
2.19
(0.45)
5.60
(0.60)
5.21
(0.36)
2.01
(0.53)
3.78
(0.37)

1.29
(0.17)
3.76
(0.37)
2.50
(0.14)
1.85
(0.24)
2.52
(0.38)

35 °C
(308 K)

1.86
(0.12)
2.78
(0.32)
ND
ND
ND

Table 3: ic2 Peptide Mimic Effect on Kd of 8-OH-DPAT
This table is a summary of the dissociation constants (Kd) calculated for the ligand [3H]-8-OHDPAT in the absence and the presence of H5HT1aR ic2 peptide mimics at different temperatures.
Minimums of two independent experiments were done at each temperature for each peptide. The
Kd is the concentration of [3H]-8-OH-DPAT at which 50% of the receptor ligand-binding sites are
occupied. Values in the table are Kd for agonist, values in parenthesis are standard error of the
means (SEM). ND = not done.
Statistics:
Across row comparisons, 0-35C, left to right; only significant differences are listed; all other nonsignificant comparisons are not listed (unless otherwise noted):
8-OH-DPAT: p < 0.05 for 0/30, 15/30
P11: p < 0.05 for 0/15, 0/25, 0/30, 0/35, 15/30
P22: p < 0.05 for all comparisons.
P23: p < 0.05 for 0/15, 0/25, and 0/30.
P24: none of the comparisons were statistically significant. Part of this result is because of a large
error bar for 0 degrees.
Down Column Comparisons, top to bottom, only significant differences listed, unless otherwise
noted:
0°C: p < 0.05 for DPAT/P11, DPAT/P22, DPAT/P23, P11/P23, and P22/P23.
15°C: p < 0.05 for DPAT/P11, DPAT/P22, P11/P22, P11/P23, P22/P23, and
P22/P24.
25°C: p < 0.05 for DPAT/P11, DPAT/P22, P11/P23, and P22/P23.
30°C: p < 0.05 for DPAT/P11, DPAT/P22, and P11/P23.
35°C: The only comparison, DPAT vs. P11 is not statistically significant.
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Figure 8: P23 Kd Plot at 15 °C and 30 °C
A modified Lineweaver Burke plot showing the difference in the specific
binding of [3H]-8-OH-DPAT at 15 °C (upper line, diamond shape) and 30 °C
(lower line, square shape). The Kd is the inverse of the x-intercept. The inverse
of the y-intercept is the amount of drug specifically bound to the receptor. 15 °C
y = 79.272x + 31.573 r = 0.9023; 30 °C y = 32.772x + 15.995 r = 0.9985

The determination of the Kd of [3H]-8-OH-DPAT over a range of temperatures
allows for the calculation of the standard thermodynamic parameters Gibb’s free energy
(ΔG°), enthalpy (ΔH°), and entropy (ΔS°). Gibbs Free Energy is the energy required for
a chemical reaction to proceed (change in energy based upon ligand binding in these
experiments), a negative number means the reaction proceeds spontaneously.
The enthalpy is a sum of all energy in a reaction (or binding event), which is indicative of
whether the reaction requires an input of energy to proceed or if it releases energy. A
negative number means the reaction is exothermic (releases energy) and is thus more
energetically favorable. The entropy is calculated from Gibb’s free energy and the
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enthalpy; it is a measure of the disorder of the system. For a system to overcome disorder
it takes an input of energy. In highly organized biological systems, energy is required to
maintain the order for the system to function properly. A positive number is favorable
entropy.
Gibb’s standard free energy (ΔG°) was calculated for [3H]-8-OH-DPAT alone,
and in the presence of the ic2 peptides P22, P23, and P24 (Table 4). All of these values
were negative, which is energetically favorable meaning that the binding event will occur
spontaneously. The calculated value of ΔG° is not significantly altered by the addition of
the ic2 peptides. This means that the peptides are not changing the ligand binding
reactions energetics. Thus the difference in amount of ligand bound to receptor observed
is not due to the peptides increasing the energy required for the ligand to bind to the
receptor, it can still occur spontaneously. This supports the hypothesis that the peptides
are acting at the receptor-G protein interface and not at the ligand binding site.
The enthalpy (ΔH°) is calculated from the slope of the regression line in the Van’t
Hoff plot (Figure 9, Table 4). The slope of the lines in the Van’t Hoff plot is variable for
ligand with the addition of the ic2 peptides, with the [3H]-8-OH-DPAT alone (lowest line
in the plot on the y axis, progressing upward are the lines for P23, P22, and P24) having
the flattest slope. This yields a positive (unfavorable) enthalpy; however, compared to
the slopes of the lines for which P22, P23, and P24 have been introduced to the binding
assay, it is less unfavorable without their presence. Thus the ligand requires more energy
from the system to bind the receptor in the presence of the peptides.
The entropy (ΔS°) was calculated for [3H]-8-OH-DPAT alone and in the presence
of the ic2 peptides (Table 4). The peptides increased the entropy of the [3H]-8-OH-
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DPAT binding system compared to the ligand alone. This indicates the peptides increase
the entropic favorability of [3H]-8-OH-DPAT receptor binding. The net effect of this is
the ligand binding to the receptor is driven by entropy, and able to overcome the effect of
the unfavorable enthalpy. This means that the peptides increased the order of the ligand
binding system making it more favorable for the ligand binding to occur.
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Figure 9: Van’t Hoff plot for P22, P23, and P24. Negative slopes
indicate the positive enthalpies (ΔH°) calculated for each peptide, thus
making the receptor G-protein coupling energetically unfavorable. [3H]8-OH-DPAT alone (lowest line in the plot on the y axis), P23 line is next
above followed by P22 line, and P24 has the highest y-intercept
Van’t Hoff regression equations:
Control:
y = -0.052x + 37.691; r = 0.96
P22:
y = -0.090x + 49.35; r = 0.98
P23:
y = -0.077x + 46.01; r = 0.99
P24:
y = -0.088x + 48.93; r = 0.95
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Compound
[3H]-8-OH-DPAT
(Alone)
P22
P23
P24

ΔG° (kJ/mole)
-49 (10)

ΔH° (kJ/mole)
43 (4)

ΔS° (J/mole)
311 (47)

-47 (3)
-49 (13)
-48 (5)

124 (13)
64 (6)
86 (13)

547 (49)
380 (68)
452 (57)

Table 4: ic2 Peptide Mimic Effect on Gibbs Free Energy, Enthalpy, and Entropy of
8-OH-DPAT
Thermodynamic parameters were determined in a minimum of two independent
experiments. Gibb’s standard free energy (ΔG°) was calculated from [3H]-8-OHDPAT Kd at the standard temperature 25 °C (298 K). The enthalpy (ΔH°) was
determined from the slope of Van’t Hoff plots. The entropy (ΔS°) was then
calculated from the Gibb’s Free energy equation using the experimental values
determined for free energies and enthalpies.
Statistics:
Entropy: None of the values are significantly different from control or from each
other.
Enthalpy: P22 vs. control, p < 0.05. None of the other values differ significantly.
different than control or vs. each other.

29

Incorporation of γ-[35S]-GTP into G protein; HYPOTHESIS: The N-terminal region of
ic2 is mostly involved in coupling to rather than activation of the G protein.
The basis for the hypothesis is the preliminary work with peptide P11 for ic2.
This peptide was shown to interfere with the receptor-G protein coupling, but had no G
protein activation properties. Thus a study for all of the ic2 peptides’ effect on G protein
activation was undertaken to support the hypothesis. The stimulation of the G protein to
exchange GDP for GTP is an important step in the signal transduction cascade initiated
by 5HT1aR activation. The measurement of the hydrolysis of GTP to GDP can be done,
but is challenging. Therefore, an analogous binding assay procedure was developed
using a thioester analogue of GTP. The thioester analogue γ-[35S]-GTP is about ten times
more resistant to hydrolysis by Giα (GTP 6 pmol/min/mg protein vs. γ-[35S]-GTP <0.6
pmol/min/mg protein) (Wieland et al., 1994). The introduction of the ic2 peptide mimics
had the following affect on γ-[35S]-GTP into Giα (Table 5, Figure 10). The control level
of basal GTP incorporation in the absence of 5HT or peptide is set as 100%. The
addition of 5HT increased the incorporation of γ-[35S]-GTP to 168±12%(vs. control,
p<0.05). The addition of the peptides P11, P22, P24, P25, P26, and P27 stimulated
incorporation from 100-148% of control, all less than the ligand 5HT. P21 stimulated
incorporation to 158±11% of control. P23 was the only peptide which showed a
stimulation of incorporation better than 5HT (188±10% of control).
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Treatment

Percent
γ-[35S]-GTP
Incorporation

Control
5HT (10^-7 M)
P11 (10 uM)
P21 (30 uM)
P22 (30 uM)
P23 (30 uM)
P24 (30 uM)
P25 (30 uM)
P26 (30 uM)
P27 (30 uM)

100
168
100
158
128
188
146
126
111
130

Standard
Error of
the
Mean
7
12
3
11
9
10
17
10
9
7

Table 5: ic2 Peptide Mimic Effect
on γ-[35S]-GTP into Giα
Cumulative values for all 5HT1aR
ic2 peptide mimics are shown for
affect on the incorporation of γ[35S]-GTP into Giα. All values are
percent of control. P23 stimulated
GTP incorporation is notably
greater than the ligand 5HT (188%
vs. 168% of control).
Statistics:
In the comparison of either 5HT or
each peptide vs. control all are
significant at the p < 0.05 level,
except: P11, P25, and P26.

Peptide Effect on γ-[35S]-GTP
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Figure 10: ic2 Peptide Effect on γ-[35S]-GTP incorporated into Gi
A measure of G protein activation. Control is the basal amount of γ-[35S]-GTP
incorporated into Gi in CHO cells expressing the human 5HT1aR, set as 100%. The
Y-axis is the percent of specifically bound γ-[35S]-GTP. All other treatments are
percents of the control value. P23 stimulated GTP incorporation is notably greater
than the ligand 5HT (188% vs. 168% of control). All peptides are 30 uM
concentration, 5HT 10-7 M concentration.
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cAMP Production by Adenylyl Cyclase; HYPOTHESIS: The N-terminal region of ic2 is
primarily involved in coupling to, rather than activation of, the G protein and its second
messenger cAMP.
G protein activation can be measured directly by measuring incorporation of GTP.
However, incorporation of GTP does not mean that the G protein is fully active. To be
fully active the G protein has to bind GTP and dissociate from the receptor to affect
adenylyl cyclase’s production of cAMP. This step in the 5HT1aR signal transduction
pathway following the activation of Gi is the inhibition of cAMP production by AC. The
experiments designed measured the effect of ic2 peptides on the intracellular levels of
cAMP following the stimulation of AC with FSK in the presence of the
phosphodiesterase inhibitor IBMX (an inhibitor of cAMP metabolism). FSK stimulates
AC to produce cAMP, making the determination of cAMP concentration easier. The
control value 100% represents treatment of the CHO cells with FSK, in the absence of
5HT and ic2 peptides (Figure 11, Table 6). The addition of FSK and 5HT to the cells led
to the decrease of cAMP via activation of Gi to 21±4% of control. This demonstrates that
the 5HT1aR signal transduction pathway is intact because activation of G protein
decreases intracellular cAMP concentration. The addition of the ic2 peptides to the FSK
stimulated cells had variable affect on cAMP concentration. The peptides P21, P26, and
P27, at 30 uM, (122±8%, 100±5.3%, 132±5.9%) were not able to decrease cAMP
concentration versus control. The combination of peptides P21, P26, and P27 (22±2%,
15.3±8.5%, 10.8±8.4%) with 5HT had no effect of the action of the 5HT mediated
decrease cAMP in the FSK treated cells.
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The peptides P22 and P25, at 30 uM, were slightly active at decreasing cAMP
concentration in FSK treated cells (71±2%, 64±3%). The combination of P22 and P25
with 5HT showed an additive effect at decreasing cAMP concentration (4±1%, 12±6%)
in FSK treated cells, which was better than 5HT alone. The peptides P23 and P24 were
the most active at decreasing cAMP concentrations in FSK treated cells (42±4%,
45±7%). The combination of P23 and P24 with 5HT also showed an additive effect at
decreasing cAMP concentration (15±3%, 12±7%) in FSK treated cells, which was also
better than 5HT alone.
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Production
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Figure 11: ic2 Peptide Effect on Forskolin Stimulated cAMP Production
A measure of activated G protein regulation of adenylyl cyclase. Forskolin (FSK)
stimulated cAMP production by adenylyl cyclase (AC) in CHO cells expressing
the human 5HT1aR. FSK is the control, which is set to 100%. All other
treatments are expressed as a percent of the control value. All treatments include
isobutylmethylxanthine (IBMX) an inhibitor of the metabolism of cAMP by
phosphodiesterase.
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Treatment
FSK
5HT
P21
P21/5HT
P22
P22/5HT
P23
P23/5HT
P24
P24/5HT
P25
P25/5HT
5HT/P26
P26
5HT/P27
P27

cAMP
SEM
% of Control
100
6
21
4
122
8
22
2
71
2
4
1
42
4
15
3
45
7
12
7
64
3
12
6
15.3
8.5
100
5.3
10.8
8.4
132
5.9

34

Table 6: ic2 Peptide Mimic Effect
on cAMP Concentration
Cumulative values for all 5HT1aR
ic2 peptide mimics are shown for
effect on forskolin (FSK)
stimulated cAMP production.
These experiments represent the
downstream effect of G protein
activation. All values are percent
of control FSK.
Statistics:
In the comparison of either 5HT
alone or the various peptides alone
vs. FSK control, all are significant
at the p< 0.05 level except: P26.
In the comparison of each peptide
in combination with 5HT vs. 5HT
alone, none are significant at the
p< 0.05 level except: P22/5HT.

Peptide

Low Affinity Ligand
Binding

High Affinity Ligand
Binding

Figure 12: Low Affinity Versus High Affinity Ligand Binding
Intracellular loop peptide mimics interference with specific ligand binding.
The introduction of the small peptide probes into the binding assay
uncouples the receptor and Gi. The uncoupled receptor shifts the receptor to
its low affinity ligand binding state. This was measured in the [3H]-8-OHDPAT vs. 5HT1aR binding assays. The low ligand binding affinity Kd for 8OH-DPAT at 5HT1aR is 22 nM (Fargin et al., 1988). The experimental value
of Kd from our experiments were high affinity Kd range from about 0.6 to
1.3 nM. The difference between Kds being 20 nM for their low affinity Kd
and about 1 nM for our high affinity Kd, then we are looking at a 20 fold
difference, an easily measurable difference.
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Discussion
Binding and Thermodynamics: The general outcome of peptide action in the
agonist inhibition format (Table 2) is summarized schematically in Figure 12. Peptides
P21-27 have differential capacity to uncouple the receptor-G protein complex, and the
accompanying thermodynamic results with peptides in the middle of this group (P22-24)
may add insight on these differential processes (Tables 3 & 4). Work previously done has
established the role that enthalpy and entropy play in receptor ligand binding in the betaadrenergic receptor, dopamine receptor, opioid receptor, adenosine receptor (Heitman et
al., 2006), rat 5HT1aR, and human 5HT1aR receptor systems. In the β-adrenergic
receptor system studies by Weiland et al. (1982), it was found that β-adrenergic agonists
yield more favorable enthalpic changes and unfavorable entropy changes. In comparison,
β-adrenergic antagonists were found to have less favorable enthalpic changes and more
favorable entropies. The dopaminergic receptor system studies by Zahniser et al. (1983)
found that the displacement of bound antagonists and agonists is entropically driven, and
changes in temperature have little effect on agonist displacement. The opioid receptor
system studies by Hitzemann et al. (1982) show that agonist binding is associated with
favorable entropies and unfavorable enthalpies, while opioid antagonist binding is
associated with favorable enthalpies and entropies. The central idea to be taken from
these experiments is that each GPCR studied has unique thermodynamic parameters that
govern its functionality.
The experiments with [3H]-8-OH-DPAT alone for the rat 5HT1aR done by
Dalpiaz et al., 1995 found a negatively sloped Van’t Hoff plot while our data for
H5HT1aR has a flatter slope but still negative trend. The standard free energies for the

36

rat and human 5HT1aR are similar (-51.3 versus -49 kJ/mole). The shallower slope of
the H5HT1aR Van’t Hoff plot compared to the rat receptor yields a more favorable
enthalpy of 43 versus 58 kJ/mole. This trend is reversed in respect to entropy. The rat
5HT1aR has more favorable entropy vs. the human receptor 366 vs. 311 J/kmole. These
findings possibly indicate that [3H]-8-OH-DPAT ligand binding is less entropically
driven in the human than rat 5HT1aR (Hall et al., submitted 2008).
Thiagaraj et al. 2005 compared the thermodynamics of ligand binding to
H5HT1aR for the agonists dipropyltryptamine (DPT) and [3H]-8-OH-DPAT. DPT, the
larger of the two agonists, has a smaller negative standard free energy -45 kJ/mole, and
larger enthalpy 107 kJ/mole and entropy 510 J/mole (8-OH-DPAT thermodynamic
parameters: ΔG°=-49, ΔH°=43, ΔS°=311). Thus, the binding of DPT to H5HT1aR
seems to be more driven by entropy compared to the binding of [3H]-8-OH-DPAT. This
difference is possibly thermodynamic evidence showing that the more energetically
favorable binding of [3H]-8-OH-DPAT makes it a full-agonist (sub-nanomolar Kd) when
compared to DPT (micromolar IC50), which is a partial agonist.
These experiments differ from the current study because they used agents which
directly compete at the same site at which the agonist binds. In our experiments the
5HT1aR intracellular loop peptide mimic is hypothesized to be acting at the receptor-G
protein interface, which affects the receptor’s ligand binding affinity state. This resulting
change in affinity affects the thermodynamics of receptor binding to varying degrees (8OH-DPAT @5HT1aR low affinity Kd = 20 nM, high affinity Kd = 1 nM).
The current thermodynamic study focuses on the ic2 peptides P22, P23, and P24.
These peptides were chosen because they showed the greatest activating effect on the
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5HT1aR signal transduction system. The study measured the changes in the Kd of [3H]8-OH-DPAT in the presence of these peptides at temperatures of 0°C, 15°C, 25°C, and
30°C. The introduction of the all peptides caused an increase in the Kd for [3H]-8-OHDPAT as the temperature of the binding system decreased. The magnitude of effect of
the different peptides on [3H]-8-OH-DPAT specific binding was not the same. Generally
speaking, P22 and P24 had a similar effect both on Kd, enthalpy, and entropy. This
seems to mirror the effectiveness of the peptides at activation of the signal transduction
cascade. The general trend observed is that P23 contains the core region of ic2, which is
responsible for G protein activation. As the peptides, especially to the N-terminal side of
P23, move away from this core region, they show diminished G protein activation
properties and more involvement in G protein coupling (Table 2, Figures 10 & 11). The
results for P11 (G protein coupling but no activation activity), an ic2 peptide from a
previous study, would likely be similar to those for the ic2 carboxy terminus peptide P27
if a thermodynamic study is completed for P27.
Effect of Peptides on G Protein Activation and Signal Transduction: These data collected
in our experiments with P23 support that this peptide mimic has the most agonistic like
properties of all the ic2 peptide mimics tested. These data measured G protein activation
(based upon amount of γ-[35S]-GTP incorporated into Giα) and negative regulatory affect
on AC (based upon the decrease in FSK stimulated cAMP production). When the
thermodynamic data for Kd, standard free energy, enthalpy, and entropy for P23 is
compared to that for the agonist, [3H]-8-OH-DPAT some similarity is evident. P23 has
the least additional effect of all the peptides on increasing the Kd of [3H]-8-OH-DPAT as
temperature decreases. None of the peptides which were tested yielded a significant
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change in the standard free energy from that of the agonist [3H]-8-OH-DPAT (p>0.05).
This means that none of the peptides affected the spontaneity of the ligand binding event.
All of the peptides showed unfavorable increases in enthalpy compared to the agonist
[3H]-8-OH-DPAT. This means that in order for that agonist to bind to the receptor a net
input of energy was required in the presence of the peptides. All of the peptides showed
favorable increases in entropy compared to the agonist [3H]-8-OH-DPAT. This means
that the organization of the binding system increased in the presence of the peptides,
accompanied by increased disorder elsewhere in the system.
The increases in enthalpy and entropy for the peptides mirrored the results from
the Kd with P23 being the most similar in properties to [3H]-8-OH-DPAT. The lines in
the Van’t Hoff plot for [3H]-8-OH-DPAT and P23 are also the closest in slope compared
to other peptides tested. Our interpretations of these results are that P23 acts most like
the agonist. Possibly due to P23 having the least additional affect of all the peptides on
the conformation of the receptor and G proteins, necessary for the activation of the signal
transduction cascade. These changes are very similar to those induced in the complex by
the bound agonist.
Data collected in these experiments with regard to the signal transduction cascade
of 5HT1aR have implicated a role for ic2 in receptor coupling and G protein activation.
The amino terminus end of the loop involving the sequence IALDRYWAITDPIDYV and
including peptides P11-P23 is important for coupling to the G-protein. Evidence for this
includes the highly conserved DRY sequence and the IC50 activity for the peptides,
which ranges from 7-30 uM. The decay of G protein coupling and activation activity was
observed as the peptides progress towards the carboxy terminus of ic2. However, as the
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amino acids seem to wane in importance for receptor coupling they increase in
importance for G protein activation with its peak at the P23 amino acid stretch
WAITDPIDYV. This is clearly shown by the bell shaped progression of the data bars for
the incorporation γ-[35S]-GTP into Giα(Figure 10). This can be superimposed over the
inverted bell shaped depression in the data bars for the intracellular levels of FSK
stimulated cAMP production (Figure 11). The carboxy terminal end of ic2 consisting of
the amino acids RTPRPR may be important as simply as space occupiers in the receptor
protein chain. This stretch of amino acids in the carboxy terminal end of ic2 serves as a
space filler, holding the amino terminal of ic2 in a favorable orientation for coupling to
the G protein. Also interesting about the carboxy terminal end of ic2, is the presence of
the 2 proline residues separated by only 1 amino acid. These proline residues in close
proximity to each other introduce a kink in the receptor structure constraining its range of
motion. Overall, these experiments demonstrate the clear role for H5HT1aR’s ic2 in
coupling receptor to G protein, and toward the loop’s middle, G protein activation.
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5HT1AR INTRACELLULAR LOOP 3 SIGNAL TRANSDUCTION; HYPOTHESIS:
SEGMENTS OF LOOP 3 ARE DIFFERENTIALLY INVOLVED IN COUPLING AND
ACTIVATION OF GI.
5HT1aR Intracellular Loop 3 Introduction
The third intracellular loop (ic3) of the human 5-HT1A receptor (Turner et al.,
2004) is the largest of the receptor’s four intracellular loops. This loop is 135 amino
acids in size. It has been shown for other members of the GPCR family (β-adrenergic,
σ-opioid, 5HT2aR) that this loop is important for receptor coupling to the G protein
(Munch et al., 1991; Palm et al., 1995; Merkouris et al., 1996; Oksenberg et al., 1995).
Data representing the role of ic3 in the functionality of GPCR has also been reported in
the literature (Bikker et al, 1998; Dohlman et al., 1991). One report of deletion mutations
in GPCR is for the ic3 region of the thyroid stimulating hormone receptor (TSHR).
These mutations were reported to cause constitutive activity in the receptor protein.
Further refinement of this study identified that the deletion of D564 residue was
sufficient to cause constitutive receptor activity (Schulz et al., 1999). Constitutive
activity of this receptor leads to hyperthyroidism because it stimulates the thyroid to
produce and release more thyroid hormone.
Previous work in our laboratory using small peptide probes that mimic the amino
acid sequence of the amino terminal end of ic3 of the 5-HT1A receptor have yielded the
following results. The peptide P1 is a 15 amino acid synthetic peptide (Table 7), which
mimics the first 15 amino acids in the ic3 region of the receptor. The introduction of the
P1 peptide into a ligand binding experiment demonstrated that it was able to decrease the
specific binding of [3H]-8-OH-DPAT (Table 8). We speculated that the peptide is
uncoupling the receptor from the G protein, which shifts the receptor to its low affinity
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ligand binding state. It was also demonstrated that the introduction of the peptide affects
the signal transduction cascade by stimulating the incorporation of γ-[35S]-GTP into Gi
and decreasing the amount of cAMP generated by the stimulation of adenylyl cyclase
with FSK (Table 8). The data from these studies indicate that the RFRIR stretch of
amino acids are important for the coupling of the receptor to Gi while the
ARFRIRKTVKK stretch of amino acids is important for the activation of Gi (Thiagaraj et
al., 2002; 2007). To continue these initial studies and further elucidate the function of ic3
in G protein coupling and activation, two more peptides, P12 and P13, were tested in
ligand binding assays, γ-[35S]-GTP incorporation assays, and cAMP assays. These
peptides are 10 amino acids in length; each is shifted two amino acids towards the
receptor’s carboxy terminus (Table 7).

Compound

P1

Sequence

IFRAARFRIRKTVKK

P12

KTVKKVEKTG

P13

VKKVEKTGAD

[3H]-8-OH-DPAT [3H]8-OH-2-di-n-propylaminotetralin

Table 7: ic3 Peptide Mimics
Primary sequences of H5HT1aR ic3 loop peptides; and one non-peptide agonist.
N-terminal for each peptide is to the left. P1 is from a previous study done by
Thiagaraj et al., 2007. P12 and P13 are the ic3 peptide mimics used in our
studies. [3H]-8-OH-DPAT is a 5HT1aR agonist used in these studies.
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Peptide

Agonist (%)
Inhibition

[35S]-γ-S-GTP
Incorporation %
Above Conrol

% Inhibition of
FSK-Stimulated
cAMP

P1*

50 (3uM)

30 (1uM)

10 (10uM)

P12

28 (30uM)

24 (30 uM)

0 (30uM)

P13

50 (15 uM)

12 (30 uM)

-24 (30 uM)

Table 8: ic3 Peptide
Mimic Signal
Transduction Data
Summary of data
generated for all ic3
experiments with P12 and
P13. P1 is included as a
reference, from Thiagaraj
et al., 2007.

5HT1aR ic3 Peptide Effect on Ligand Binding
The high affinity binding of a ligand to a receptor is dependent upon the receptors
being in their high affinity ligand binding state (receptor coupled to G protein). The
effect of an experimental variable on the binding can be represented as percent of control
(100%) or by specifying the amount of inhibition relative to control. The introduction of
ic3 peptide mimic P12 at 30 µM into the ligand binding experiment, yielded a 28%
inhibition in the amount of agonist specifically bound to the receptor G protein complex
(Figure 13). P13 at 15 µM yielded a 50% inhibition of specific binding, which was
similar to P1, but required a higher concentration of peptide. In summary, both peptides
uncouple receptor and G protein as evidenced by a decrease in the amount of specifically
bound [3H]8-OH-DPAT, although P13 is more active. These data implicate this region of
H5HT1aR ic3 as important for coupling receptor to G protein. The evidence for this
conclusion is the decrease in high affinity ligand binding observed. We believe this is due
to peptide interference at the receptor-G protein interface.
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P12 Affect on Specifically Bound
[3H]-8-OH-DPAT
120
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Figure 13: P12 Concentration Dependent Displacement of Specifically Bound 8-OH-DPAT
Displacement curve for ic3 peptide P12 and [3H]8-OH-DPAT at H5HT1aR. As the
concentration of P12 increased, the amount of specifically bound [3H]8-OH-DPAT
decreased; the maximum with P12 (30 uM) is 28% inhibition of agonist binding. All data
points represented are n=8; error bars represent the SEM.

Incorporation of γ-[35S]-GTP into G protein
The binding data for the two ic3 peptides P12 and P13 suggest that the peptide is
uncoupling the receptor from its G protein. To investigate if the peptide binding leads to
activation of the G protein, experiments were designed to measure the incorporation of γ[35S]-GTP, a more stable thioester analogue of GTP, into Gi. Its incorporation is a well
established measure of G-protein activity. Interestingly, both peptides (30 µM) were able
to stimulate the incorporation of γ-[35S]-GTP into Gi at a significantly greater rate than in
control experiments (P12 124±6, P13 112±6 vs. control 100, p<0.01) (Figures 14 and 15).
Neither peptide was able to stimulate as much incorporation of γ-[35S]-GTP as 5HT
alone; however, when combined (5HT/P12 261±9, 5HT/P13 204±15, p<0.01) with 5HT,
they had an additive effect, which was significantly greater than 5HT alone.
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300

% Control (Sp. _-35S-GTP Incorp.)

€

261 ± 9

250

215 ± 10

200

150

*

124 ± 6

100 ± 4
100

50

0

Control

5HT (10-6M)

P12 (3*10-5M)

5HT/P12

* P12 vs. Control p<0.01
€ 5HT vs. 5HT/P12 p<0.01

Figure 14: P12 Stimulated Incorporation of γ-[35S]-GTP
A measure of G protein activation. Control is the basal amount of γ-[35S]-GTP
incorporated into Gi in CHO cells expressing the human 5HT1aR set as 100%.
The Y axis is the percent of specifically bound γ-[35S]-GTP. All other treatments
are percents of the control value. *p<0.01 P12 vs. Control; € p<0.01 5HT vs.
5HT/P12

% Control (Sp. -35S-GTP Incorp.)

300

€

250

204 ± 15

156 ± 8
200
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*

100 ± 4

112 ± 6
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50

0
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5HT (10-6M)

P13 (5*10-3M)

5HT/P13

* P13 vs. Control p<0.01
€ 5HT vs. 5HT/P13 p<0.01

Figure 15: P13 Stimulated Incorporation of γ-[35S]-GTP
A measure of G protein activation. Control is the basal amount of γ-[35S]-GTP
incorporated into Gi in CHO cells expressing the human 5HT1aR set as 100%.
The Y axis is the percent of specifically bound γ-[35S]-GTP. All other treatments
are percents of the control value. * P13 vs. Control p<0.01; € 5HT vs. 5HT/P13
p<0.01
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cAMP Production by Adenylyl Cyclase
The next step in the 5HT1aR signal transduction pathway following the activation
of Gi is the inhibition of cAMP production by AC. These experiments measured the
effect of P12 and P13 on the intracellular levels of cAMP following the stimulation of
AC with FSK in the presence of the phosphodiesterase inhibitor IBMX (Figure 16).
Treatment with P12 did not affect the concentration of cAMP. In contrast, P13
stimulated the production of cAMP greater than the control FSK. Treatment with 5HT
decreased cAMP concentrations to only 24±1 % of control as expected. The peptides
combined with 5HT (5HT/P12 41±1, 5HT/P13 60±4, p<0.05) had an inhibitory effect on
the ability of 5HT to activate Gi, which led to a decrease in its inhibitory effects on cAMP
production.

124 ± 7

125

% FSK-stimulated cAMP

100 ± 5

100 ± 6

100

60 ± 4

75

*
41± 1

*

50

24 ± 1
25

0
FSK

5HT

P12

5HT/P12

P13

5HT/P13

Treatment

Figure 16: P12 and P13 Effect of Forskolin Stimulated cAMP Production
Forskolin (FSK) stimulated cAMP production by adenylyl cyclase (AC) in CHO
cells expressing the human 5HT1aR. These experiments were a measure of second
messenger regulation by G protein. FSK is the control, which is set to 100%. All
other treatments are expressed as a percent of the control value. All treatments
include isobutylmethyl-xanthine (IBMX) an inhibitor of the metabolism of cAMP.
5HT vs. 5HT/P12 and 5HT vs. 5HT/P13 *p<0.05
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H5HT1aR ic3 Discussion
The ic3 region of the 5HT1aR covered in these studies is quite small compared to
the overall size of the loop. However, the differential activities of the peptides at
different steps of the signal transduction cascade (Table 8) give some clues about the
function of the segment of the receptor that the small peptides P12 and P13 are
antagonizing. The decrease in the amount of [3H]8-OH-DPAT specifically bound to the
5HT1aR is important because it indicates a change in the receptor’s affinity for the
ligand. The mechanism proposed for this is that introduction of the small peptide mimics
of the amino end of ic3 are interfering with the coupling of the 5HT1aR with Gi. The
decrease in coupling efficiency causes fewer receptors to be in their high affinity ligand
binding state thus, fewer [3H]8-OH-DPAT molecules are able to bind to the receptor.
The activity of the G protein as measured by the incorporation of GTP into Giα is
an important indication of the activation of the signal transduction cascade. The increase
in γ-[35S]-GTP incorporation following the introduction of the peptides P12 and P13 into
the experimental system indicates that the amino acid residues in this ic3 region are
important not only for receptor coupling, but also for activation of the exchange of GDP
for GTP in Giα. It is important, however, to note that neither of the peptides is as efficient
as 5HT at stimulating the exchange. Interestingly though, when the peptides are
combined with 5HT, they have an additive effect on the incorporation of γ-[35S]-GTP.
This suggests that they are working independently: 5HT through the receptor Gi
complex, and the peptides acting directly at uncoupled Gi. There is also an indication
that the ability of ic3 to directly activate Gi is due to the amino acid run of
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ARFRIRKTVKK with the activity of the peptide mimics decreasing as they include less
of this sequence (P1>P12>P13) (Table 7).
The inhibition of AC by Gi is an important negative regulator of intracellular
signal transduction. The peptides tested, P12 and P13, differed in their ability to regulate
this step in the cascade. P12 was unable to decrease the FSK stimulated levels of cAMP.
This is in contrast to the action of 5HT which was able to significantly decrease the FSK
stimulated levels of cAMP via activation of Gi. The combination of 5HT and the
peptides decreased the affect of 5HT on lowering intracellular cAMP concentration.
P13 had the opposite effect; it increased cAMP concentrations! This suggests that the
two new amino acids (AD) from ic3 are the beginning of a new region of the loop, which
has negative regulatory properties on Gi blunting its normal ability to regulate AC. It is
interesting to speculate regarding the differences in data from the γ-[35S]-GTP
incorporation assays and cAMP assays. With the relatively small changes produced by
these two peptides, one possibility is experimental error that has not been accounted for.
Another possibility is that the peptides are acting at some site or sites other than the
proposed receptor-G protein interface or that the process at the interface is more
complicated than anticipated or both.
The most tantalizing possibility is that the newly explored region represented by
P12 and P13 is the beginning of a region of ic3 involved in coupling of receptor to G
protein and is still capable of participating in activation of Gi. Additionally, however, the
activation of Gi in this case involves additional conformational changes that inhibit rather
than activate Gi. This would produce the opposite effect on cAMP concentration than
anticipated, and would be equivalent to the downstream actions of an inverse agonist at
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the ligand binding site. Since 5HT1aR is capable of constitutive activity (Martel et al.,
2007), inverse agonism is possible, and it will be fascinating to see if the P12/P13 region
is involved in this speculative activity once the crystal structure for the receptor has been
determined.
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DISCUSSION: H5HT1AR IC2 AND IC3 SIGNAL TRANSDUCTION
The peptide mimic study for the intracellular loops (ic) 2 &3 of the 5HT1aR was
begun with the hypothesis: Segments of loop 2 are differentially involved in coupling and
activation of Gi. From previous work in the lab, we determined that use of sequential ten
amino acid truncates of ic2 and ic3 would suggest differentiation of the function for
corresponding sections of the receptor protein (Thiagaraj et al., 2007). The functions
referred to in the hypothesis are the coupling of the G protein to the receptor and upon
agonist binding to the receptor’s ligand binding-site, activation of the coupled G protein.
A related second hypothesis expanded analysis into the thermodynamic realm:
Peptides from intracellular loop 2, active in experiments conducted in aim 1, will
increase the system’s entropy, altering the interaction between agonist and receptor. The
data presented in this section is for peptides (P22-24), which showed the most activity in
the 5HT1a receptor signal transduction system in the first specific aim (GTP
incorporation and cAMP production).
The last hypothesis broadened analysis by moving from ic2 to ic3: Segments of
loop 3 are differentially involved in coupling and activation of Gi. The use of ten amino
acid truncates of ic3 would allow the differentiation of the function of the corresponding
section of the receptor protein. The functions referred to in the hypothesis are the
coupling of the G protein to the receptor and upon agonist binding to the ligand bindingsite, activation of the coupled G protein. Work on this final hypothesis actually started
before the ic2 loop studies because previous work in the lab had emphasized ic3
(Hayataka et al., 1998; Ortiz et al., 2000). However, from a strategic standpoint, we
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decided to focus on ic2 in the current investigation. There is a greater than five fold
difference in size of the two loops, and we concluded that systematic investigation of ic3,
exceeded the temporal scope of this project. Nevertheless, 2 peptides were tested in this
study, and we feel the results obtained contribute to the previously studied peptides from
ic3.
There are some aspects of the previous work that help provide context for the
current work. Conversely, some of the new results provide perspective to the previous
work that was not possible before. Aspects of peptide specificity are vital to estimating
the generality of the results reported here. There are two aspects of specificity of key
importance: the site or sites of action for the peptides; and the peptides’ ability to gain
access to those sites of action. Somewhat less crucial to the current thesis, but meaningful
overall, has to do with generality of these results across species as the source of receptor
in the current series of investigations has been exclusively human.
A synopsis of these specificity parameters follows: During the original work,
started over ten years ago, there was considerable effort devoted to developing multiple
types of controls. A peptide of similar size (bombesin), but different sequence from
parent peptide P1 (from ic3’s N-terminus), was inactive in all of our measures. Another
peptide (P10) from H5HT1aR’s C-terminus that we hypothesized to be active, was not
(Thiagaraj et al., 2002). These results gave confidence that not just any peptide we put
into the system was active. Further, truncates and substituted derivatives of P1 gave
differential activities in our various measures of coupling and activation. For example, a
small peptide (P6) from ic3’s N-terminus was inactive in all measures; another small
peptide with residues from the mid-section of P1 was active in uncoupling, but was
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inactive in signal transduction; P2, a substituted derivative of P1 was less active in
uncoupling but more active in signal transduction than P1. These types of results gave us
further confidence that activity was sequence-dependent (matching the sequence of ic3)
and not the random result of testing just any peptide.
Initially, we were quite concerned about a peptide’s ability to gain intracellular
access to the putative sites of action at the receptor-G protein interface. Accordingly,
early studies with the ic3 parent P1 and its relatives (P2-9) and the ic2 parent P11 were
done with three different types of receptor preparations: whole cell, membrane, and
solubilized (Hayataka et al., 1998; Ortiz et al., 2000; Thiagaraj et al., 2002; Thiagaraj et
al., 2007). This approach is very time consuming and the solubilized format is extremely
difficult because of receptor lability. Although some differences were noted, generally
the membrane preparations were highly representative of all results in the agonist
inhibition assays. Thus, in the current study, membrane preparations were used
exclusively in the agonist inhibition format.
The question always arises, as well it should: Do the peptides cross the cellular
membrane? We have not directly addressed this question, but synthetic and naturally
occurring peptides from wasp venom that are similar to the H5HT1aR peptides have been
shown to gain intracellular access via yet poorly understood mechanisms (Mousli et al.,
1990). The current studies still use the whole cell approach in the cAMP assays; so
differential intracellular penetration could still be a problem. The current work provides a
reasonable, but not completely equivalent, comparator for signal transduction by
conducting GTP incorporation into the G proteins using membrane preparations.
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We postulate peptide sites of action as being intracellular either at the G proteinreceptor interface or at the surface of the receptor or G protein, but not at, for example,
the ligand binding-site. Early work in the lab looked into this issue by conducting binding
experiments in which both agonist and peptide concentrations were variables (viewed in
double reciprocal, Lineweaver-Burk-like graphs similar to those provided in the
thermodynamic section of this dissertation). Examples from these studies include a
somewhat longer version of P1, P8, that shows a non-competitive mechanism and P11,
that gives an uncompetitive mechanism (Thiagaraj et al., 2007). These conclusions gave
credence to the postulate that the test peptides are either, not competing for, nor
mimicking agonist at the ligand-binding site, in comparison to an agent like DPT that is a
ligand-binding site directed partial agonist (Thiagaraj et al., 2005).
Finally, what implications for 5HT1aR from other species do these human
peptides have? A small amount of previous work in the lab addresses this matter by using
rat brain receptor, which has been sequenced (Albert et al., 1990; Lembo et al., 1997),
and rabbit brain receptor (Weber et al., 1997), in which our laboratory has partially
characterized the un-sequenced receptor. P1 and P2 (ic3 peptides) gave similar results to
human receptor in agonist inhibition (Hayataka et al., 1998; Ortiz et al., 2000), an
expected result as the rat and human receptors are highly homologous and all three
receptors have almost identical biochemical pharmacology. Although highly interesting,
use of these peptides against other 5HTR’s and other related GPCR’s such as the beta
adrenergic receptor have not been done. Overall, these previous studies provide evidence
that the peptides under study are reasonably specific, but not perfect, tools that also have
some generality in the sense of comparative biology.
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Changes in Receptor Binding Affinity: Focus on the Ligand Binding-Site
The introduction of the ic2 and ic3 peptide mimics had variable effect on the
specific binding of an agonist. Agonist binding to a GPCR is complicated. It requires
that all of the various pieces of the puzzle be in the proper orientation at the same time.
The agonist in this case, 8-OH-DPAT, binds with the most robust intermolecular
interactions when the 5HT1a receptor is coupled to Gi. The coupling of the two proteins
changes their conformations, leading to superior agonist binding; this is referred to as the
receptor’s high affinity agonist binding state (Maguire et al., 1977; Peroutka et al., 1979).
The hypothesized role for the small peptide mimics in this system is to disrupt the
receptor-G protein coupling (Hayataka et al., 1998). The disrupted coupling of the
proteins causes a decrease in the amount of agonist that can bind to the receptor because
the receptor conformation has been shifted to its low affinity agonist binding state.
While the scope of this dissertation has largely been bordered by the receptor-G
protein interface, a few observations relative to the ligand binding-site itself should be
useful in context of the larger receptor-G protein system. A large literature has developed
with respect to both ligand binding-site determinants in GPCR generally (see for
example, to start this literature: Dohlman et al., 1991), 5HTR (Hoyer et al., 1994; Barnes
and Sharp, 1999), and the 5HT1aR, specifically (Raymond et al., 1999; Robichaud and
Largent, 2000).
These developments have centered around understanding of the GPCR prototype,
rhodopsin, via its crystal structure (Palczewski et al., 2000). Of great hindrance to the
GPCR field has been the lack of crystallographic information for any of the other
hundreds of receptors in the superfamily (Baldwin 1993, 1994; Sprang 2007). One of the
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major goals of the current peptide project was to help, by contributing biochemical and
pharmacological information that, in conjunction with many other techniques used by
other investigators, piece together insights into receptor structure and function in light of
the crystallographic deficit.
Additionally, studies summarized in the first two appendices of this dissertation
and in previously documented work (Thiagaraj et al., 2005; Russo et al., 2005) are
directly relevant to H5HTR’s ligand binding-site. It is tremendously exciting that during
the writing of this dissertation, the first crystal structure for a GPCR other than rhodopsin,
5HT1aR’s close relative, the beta 2 adrenergic receptor (βAR), has been reported
(Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007). Ramifications
of this revolutionary development (Day et al., 2007; Kobilka, 2007; Kobilka and Deupi,
2007) will be briefly discussed below.
Changes in Specific Agonist Binding: Focus on the G Protein Interface
The most efficient uncouplers from the ic2 region were P21-P23 (also P11),
which decrease the amount of specifically bound 8-OH-DPAT to 50% of control. These
data demonstrate that the N-terminal region of ic2 is important for coupling the receptor
to the G protein (ic2 amino acid sequence IALDRYWAITDPIDYV). The other ic2
peptides P24-P27 from the carboxy terminus, in contrast, have far less effect on
uncoupling the receptor from the G protein, decreasing the binding of 8-OH-DPAT to 7594% of control. These data suggest the possibility that this segment of ic2 is only
partially in contact with the G protein when it is coupled to the receptor and the
segment’s efficacy in the coupling process was minimal.
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The data collected for the amino terminal region of ic3 for P12 and P13 cause a
decrease in specifically bound 8-OH-DPAT to 73% and 50% of control, respectively.
These data suggest that this region of ic3 is important for receptor coupling to the G
protein. P12 consists of the final five amino acids of ic3 parent P1 and then proceeds five
more residues toward the loop’s center. P13 is shifted into the loop two more residues
toward the loops carboxy terminus. While the data support this region’s role in receptorG protein coupling, the peptides’ relative ability to uncouple declines relative to
previously studied peptides whose structures represent segments closer to ic3’s Nterminus. P12 and 13 are also beyond (toward the C-terminus) the key RFRI region of P1
previously identified as key to that part of ic3 responsible for G protein activation (Ortiz
et al., 2000).
Varrault et al. (1994) demonstrated that the C-terminal section of i3 is involved in
G protein coupling and regulation. So, if our work can be interpreted to mean that peak
coupling and activating properties are associated with ic3’s N-terminal residues and
Varrault’s work can be interpreted to mean that peak coupling and activating properties
are associated with ic3’s C-terminal residues, then what is the role for the vast internal
region of the loop in 5HT1aR? Variability of GPCR ic3’s size in rhodopsin versus
5HT1aR and BAR’s, which have larger ic3 loops (at least twice the size of rhodopsin’s
ic3). It would be meaningful (although arduous) to eventually extend this peptide
approach into the mid-loop region of ic3, and as a crystal structure becomes available for
5HT1aR, the comparisons of 5HT1aR loop function with BAR and rhodopsin will be
fascinating.
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G Protein Activation Measured by Incorporation of γ-[35S]-GTP
Activation of Giα is an important step in regulating the intracellular second
messenger system. The ic2 peptides had variable affect on stimulating the incorporation
of γ-[35S]-GTP into Giα. The peptides P11, P22, P24, P25, P26, and P27 stimulated
incorporation from 100-148% of control, all less than the ligand 5HT. P21 stimulated
incorporation to 158±11% of control, slightly less than 5HT. P23 was the only peptide
which showed a stimulation of incorporation better than 5HT (188±10% of control).
These data suggest a bimodal area of ic2, which very efficiently transmits changes in
receptor conformation to the G protein to catalyze the exchange of GDP for GTP in Giα.
However, the activity peak with P23 implicates this part of ic2 as being very important
for activation of Giα. The ic3 peptides P12 and P13 were weak stimulators of
incorporation of γ-[35S]-GTP into Giα.
Neither of the peptides (P12 and P13) was as potent as 5HT at activation of Giα.
Many peptides tested in combination with 5HT yielded an additive effect on stimulating
the incorporation of γ-[35S]-GTP into Giα, and were better than 5HT or the peptides alone.
This suggests that they are augmenting signal transduction through complementary
mechanisms to activate Giα. One very real possibility here is that multiple regions are
responsible for G protein activation, and the individual peptides mimic only part of this
structure, thereby producing a diminished effect relative to 5HT.
Negative Regulation of Adenylyl Cyclase (AC)
The activation of Giα by 5HT1aR causes a decrease in the intracellular cAMP
concentrations by inhibiting AC. Data for the ic2 and ic3 peptides showed variable effect
on Giα activation. The peak of this activation was observed in ic2 at P23, a matching
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depression in cAMP levels intracellularly was also observed. Interestingly P21, which
demonstrated a trend towards activation of Giα, did not inhibit adenylyl cyclase. In fact
P21 increased the intracellular cAMP concentration, the opposite of what was expected.
These data from the ic3 peptides were also interesting because P12 had no affect on
cAMP concentration. P13’s signal transduction activity bears special mention. Since the
peptide increases, rather than decreases cAMP concentration, it is tempting to speculate
that the residues represented by P13 (and possibly P21) may be involved in signal
transduction associated with inverse agonists (Gbahou et al., 2003; Urban et al., 2007).
The unique activity of previously studied P9 is also interesting in this regard
(Thiagaraj et al., 2007). P9 increases rather than decreases cAMP concentration. This is a
trend, not a significant effect, however. In respect to the GTP data, however, the unusual
effect is significant. That is, P9 decreases, rather than increases, GTP incorporation,
another effect reminiscent of inverse agonism. Turner et al. (2004) have identified a
critical calmodulin regulatory site in the TM5/i3 loop region of H5HT1aR (RKTVK).
This site is a five residue stretch in the current study within P9’s sequence
(RFRIRKTVKK). It is conceivable that the removal of the first five residues of P1 to
give P9 produces a peptide that targets this regulatory site with some specificity.
Recently, 5HT1aR has been shown to possess constitutive activity (Martel et al.,
2007). Constitutive activity of the 5HT1aR causes adenylyl cyclase to decrease the
production of cAMP down to a basal level. The βAR has also been observed to possess
constitutive activity, but rhodopsin has not. One of the key features of the crystals for
βAR is the use of the inverse agonist carazolol in solving the structure, an event that
could not occur if βAR did not have constitutive activity. An inverse agonist is a
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substance which upon binding to a receptor terminates all receptor transduced signal,
below even its resting basal level. Inverse agonism has not been explored in a concerted
sense in 5HT1aR. Would a thorough examination of the P9 region plus a trip deeper into
ic3 (as suggested by P13) and into ic2 (P21) begin to shed light on inverse agonism? This
could be a very exhilarating exploration as speculation exists that inverse agonism may
be much more common than previously thought (Gbahou et al., 2003; Urban et al., 2007).
Summary of Signal Transduction Activity
The peptides studied in this project from ic2 and ic3 of H5HT1aR were shown to
modulate the signal transduction system based upon influencing high affinity agonist
binding, G protein activation, and negative regulation of the target second messenger.
The peptides showed an inhibitory effect on the specific binding of 8-OH-DPAT
decreasing it to below 50% of control in the best cases, suggesting the uncoupling of Gi
from the receptor changing its conformation to the low affinity agonist binding state.
This effect was greatest at the amino terminal ends of ic2 and ic3. The trend in the data
for activation of Gi and the subsequent inhibition of cAMP production by AC peaks at
P23 of ic2 (that is, about mid-loop). The data on either side of this maximum shows
decreased incorporation of γ-[35S]-GTP into Giα and diminishing cAMP changes,
indicating less activity in the Giα signaling pathway.
We believe that a comparison between ic2 and ic3 with regard to structure and
activity will be similar between them. The mid loop regions of the intracellular loops
will possess similar properties for activation of the signal transduction cascade. This is
most likely due to their exposure following agonist binding and the resulting change in
structural conformation of the receptor protein. Meanwhile, the coupling of the receptor
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to the G protein is most prominent at the loops’ amino terminals. This is because
portions of the receptor are exposed to and interact with the G protein when the receptor
is in its high affinity ligand binding conformation.

Thermodynamics of ic2 Peptides
The specific binding of the radioligand [3H]-8-OH-DPAT to 5HT1aR can be
measured at a range of temperatures, which allows for the calculation of various
thermodynamic binding parameters (Hitzemann, 1998). Thermodynamics are important
measures of the functionality of GPCRs. The changes in energy input and output yield
information about the underlying mechanisms of ligand binding and intramolecular
interactions, which are necessary for proper receptor function. The dissociation constant,
Kd, is the concentration of [3H]-8-OH-DPAT at which the ligand-binding site of the
receptor is 50% occupied (McGonigle and Molinoff, 1989). The Kd, determined at each
temperature forms the basis for all of these calculations. The Kd calculation was also
determined in the presence of the ic2 peptides in parallel sets of experiments.
Gibb’s Free Energy (∆G°) is the energy required for a chemical reaction to
proceed (change in energy based upon agonist binding in these experiments), a negative
number means that the reactions proceed spontaneously. This parameter utilizes the Kd at
a single temperature (25°) in an Arrhenius-like equation for calculation of ∆G°.
Specifically, Gibb’s standard free energy (ΔG°) was calculated for 8-OH-DPAT alone
(control) and in the presence of the ic2 peptides P22, P23, and P24. All of these values
are negative, meaning that the binding event will occur spontaneously. The calculated
value of ΔG° is not significantly altered by the addition of the ic2 peptides. Thus, the
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peptides did not change the overall energetics of the system much. This is evident
because the peptides did not completely abolish agonist binding. If this occurred, the
ΔG° value calculated would be positive, which means that agonist binding would not
occur spontaneously.
The observed trend for the Kd determinations for [3H]-8-OH-DPAT at the
H5HT1aR over the range of temperatures was that temperature and Kd are inversely
related in this system; as temperature increases, the dissociation constant decreases.
Stated another way, as the temperature increases the concentration of agonist required to
occupy 50% of the agonist binding sites decreases. This experimental approach allows
for the calculation of the thermodynamic parameter enthalpy (ΔH°) in a Van’t Hoff
determination. The standard enthalpy (ΔH°) is calculated from the slope of the regression
line based upon the natural logarithm of inverse Kd vs. inverse absolute temperature.
Since enthalpy is loosely equitable to heat of reaction (or the net of bonding
changes, small and large), a negative number means the reaction is exothermic (releases
energy) thus being energetically favorable. The calculated ΔH° for 8-OH-DPAT yielded
a positive (unfavorable) enthalpy in all cases. However, the data for the changes in Kd as
a function of temperature for [3H]-8-OH-DPAT alone (controls) are generally smaller
than when the ic2 peptides P22, P23, and P24 are introduced into the binding assay.
Thus, agonist binding is barely temperature-dependent and becomes more temperature
dependent when the peptides are present. Stated another way, the agonist can bind to the
receptor at any temperature with little difference, however; the ic2 and ic3 peptide
mimics make agonist-receptor binding more temperature dependent.
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The standard entropy (ΔS°) (calculated from the standard Gibb’s free energy and
the standard enthalpy in a Gibb’s equation determination) is a measure of the disorder of
the system. The more highly ordered a system is, the more energy required to maintain
that order. A positive number is favorable entropy. The ΔS° was calculated for 8-OHDPAT alone and in the presence of the ic2 peptides. The peptides increased the entropy
of the 8-OH-DPAT binding system compared to the agonist alone. This indicates the
peptides increase the entropic favorability of [3H]-8-OH-DPAT receptor binding
(increased order of the agonist-receptor binding system, but overall increased disorder).
This favorable event compensates for the unfavorable enthalpic changes the peptides
produced, keeping the overall energetics (free energy) relatively stable. P22 and P24 had
a similar effect on Kd, enthalpy, and entropy. This seems to mirror the effectiveness of
the peptides at activation of the signal transduction cascade. The general trend observed
is that P23 contains the core region of ic2 (PIDYV), which is responsible for G protein
activation. As the peptides on either side of P23 move away from this core region, they
show fewer G protein activation properties and more involvement in G protein coupling.
Viewed in a broader perspective, a few points seem to stand out in the context of
general thermodynamic theory for receptor interactions. First, the paradigm used to
analyze receptor thermodynamics is crucial to the conclusions reached (for example, in
this study, agonist is bound to the ligand-binding site, whereas in some investigations
antagonist is bound). Second, the binding sites for different receptor systems are unique
energetically. So, energetic differences between systems have led to the theory of
thermodynamic discrimination for ligand-receptor binding (Heitman et al., 2006). That is,
although there may not be entropic versus enthalpic differences overall in comparative
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pharmacology between receptor systems, in a given receptor system various binding
events (binding of different ligands) may be so discriminated.
Thus, for example to illustrate system uniqueness, in βAR, which is a closely
related system to 5HT1aR, favorable enthalpic decreases accompanied agonist binding
(Weiland et al., 1980). At the nicotinic neuronal receptor (which is ionotropic and not
related to 5HT1aR or GPCR), agonist binding is driven by both enthalpy and entropy
(Borea et al., 2004). The entropy side of this result is like our observations. Dopamine
receptors (DAR), relatives of 5HT1aR, but more distant than βAR, give agonist binding
events that are not temperature driven, a result similar to what we have observed with the
agonist [3H]8-OH-DPAT in the H5HT1aR system (Zahniser and Molinoff, 1983;
Kilpatrick et al., 1986), and similar to rat 5HT1aR (Dalpiaz et al., 1995; 1996)
Most of our current study does not fit nicely into the direct ligand-binding site
characterization paradigm as we postulate that the peptides are only indirectly influencing
agonist binding through affinity changes accompanying receptor-G protein uncoupling.
Nevertheless, the current findings can play a role in contributing to basic molecular
understanding of 5HT1aR’s and the application of this information to new drug
development, and to the place that 5HT1aR has in the broader context of biological
receptors. This should be especially so in that we are not aware that this type of
thermodynamic information has been previously available for peptide probes of receptorG protein interactions.
It is important to also interpret the results of the thermodynamic studies from the
vantage point of the original design of the peptides as probes of the receptor-G protein
interface. The observation that the peptides have little effect on agonist free energy but

63

differentially changed enthalpy and entropy has direct bearing on the peptides’ ability to
produce displacement of agonist from the ligand-binding site via indirectly produced
alterations of affinity. In every case, introduction of peptide decreases agonist binding
(differentially between peptides), and in each measured case (peptides P8, 9, 11, 22-24), a
less favorable enthalpic change compared to control accompanies agonist binding (Hall et
al, 2008).
Significantly, in each measured case, entropy increases relative to control, an
event likely to involve alterations in lipid/aqueous order, changes likely to also influence
the receptor’s ability to perturb the G protein (a differential effect that also accompanies
peptide intervention). Long-standing, dynamic theory has been advanced to understand
general allosteric mechanisms in biological regulation (Changeux and Edelstein, 2005),
and it will be fascinating to see if these thermodynamic observations can be fit into this
rapidly advancing field when crystal structure information becomes available for
5HT1aR.
Conclusions
The peptide mimic study for the intracellular loops (ic) 2 &3 of the 5HT1aR was
designed to examine which segments were involved in coupling and activation of Gi.
The amino terminal ends of ic2 and ic3 are important for coupling the receptor and G
protein. The activation of the G protein peaks at P23 (WAITDPIDYV) in ic2 (Figure
35). The activity is decreased as the peptides move in either direction away from this
core sequence. The curious results of increased cAMP concentrations caused by some
peptides suggests that the two new amino acids (AD) from P13 are the beginning of a
new region of ic3, which has negative regulatory properties on Gi.
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The introduction of the ic2 peptides perturbed the thermodynamic norm in the
agonist binding system. A summary of the peptides effects are as follows. When the
binding data for Kd and the thermodynamic parameters of standard free energy, enthalpy,
and entropy for P23 are compared to that for the agonist 8-OH-DPAT alone, some
similarity is evident. The lines in the Van’t Hoff plot (Figure 9) for 8-OH-DPAT and P23
are the closest in slope compared to other peptides tested (that is, P23 has the least
additional effect of all peptides on increasing the Kd of 8-OH-DPAT as temperature
decreases). None of the peptides, which were tested, yielded a significant change in the
standard free energy from that of the agonist 8-OH-DPAT. All of the peptides showed
unfavorable increases in enthalpy compared to the agonist 8-OH-DPAT. All of the
peptides showed favorable increases in entropy compared to the agonist 8-OH-DPAT
alone (control), which adds credence to the original hypothesis.
Therefore, it seems from these results that P23 mimics the receptor state most like
that produced by agonist. This may be because P23 has the least additional effect of all
the peptides on the conformation of the receptor-G protein complex necessary for the
activation of the signal transduction cascade. The results reported here were initially
generated to provide biochemical input into 5HT1aR structure determination, and
certainly we have speculated in that regard. As 5HT1aR x-ray structure is solved, these
peptide results and other indirect biochemical probes of structure may or may not
completely stand up.
We believe that the favorable changes in entropy observed in the thermodynamic
experiments for agonist binding are possibly due to the peptides exclusion of water from
the receptor-G protein interface. The peptide then exerts a stabilizing effect on the
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molecular interactions between the receptor and G protein. The disruption of water
molecules cage around the receptor may allow for more degrees of freedom for the
movement of the proteins allowing them to interact a more energetically favorable
manner.
Even if the final judgement of these peptide probes is mixed in this sense, the
information produced may be useful as independent pharmacological observations. That
is, future studies in this area and pragmatic implications of the work may be most
relevant in a framework where the multiple, differential activities of the peptides can be
exploited by medicinal chemists to build unique pharmacological agents targeting
previously un-utilized sites at the receptor-G protein interfacial region.
Results for ic2 and ic3 presented in this report are interesting in perspective of the
x-ray crystal structure for human beta 2 adrenergic receptor (β2AR) that has just been
published (Cherezov et al., 2007; Rasmussen et al., 2007, Rosenbaum et al., 2007). The
long-awaited crystal structure for some GPCR other than rhodopsin should open the flood
gates for consolidation of understanding (Kobilka, 2007; Kobilka and Deupi, 2007) of
structure-function relationships within the receptor superfamily. It is perhaps fitting to
think about the relatively open, less structured βAR (and likely 5HT1aR) compared to
rhodopsin as this dissertation closes (Cherezov et al., 2007).
Unstructured segments of these receptors are a problem in creating proper
crystals. One of the most unstructured regions in β2AR is the third intracellular loop,
which is much larger in β2AR than rhodopsin (even larger still in 5HT1aR). One of the
current β2AR studies basically involved cutting out the third intracellular loop and
inserting an enzyme (T4 lysozyme) known to produce nicely stacked crystals (Day et al.,
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2007). Alternatively, in the companion study a rigid antibody (Mab5) was bound to the
third intracellular loop. In both cases, the highly disordered carboxy-terminus of the
receptor was removed. While methodological, these considerations point beyond
technique to differences between β2AR (and presumably 5HT1aR) and rhodopsin. The
less structured, more open, nature of β2AR points to greater conformational and
functional complexity.
The G 21 clone of the H5HT1aR used in our experiments has 43% homology with
Human β2AR in the TM domains (Kobilka et al., 1987, Fargin et al., 1988). The greatest
homology is in TM6 where 19 of 20 amino acids are identical (an astounding 95%
homology). Intracellular loop 2 is well-conserved between the two receptors, but ic3 and
the C-terminus are not. This paper also has a print out of the residue by residue
comparison of the 5HT1aR vs. β2AR (Fargin et al., 1988).
Regarding the comparison between H5HT1aR and β2AR relative to effector
activation or signal magnitude, Fargin et al. (1989) transiently transfected the H5HT1aR
clone and the BAR2 clone into two types of cultured cells. Using 5HT concentrations
similar to what we used, and appropriate isoproterenol (β2AR agonist) concentrations,
they were able to achieve about equal magnitude effects for cAMP production, but in
opposite directions (β2AR is a positive regulator of adenylyl cyclase). I interpret this to
mean that the two receptors have about the same magnitude effect on signal transduction
but opposite in sign intracellular effect at equivalent doses for the appropriate receptors.
Our results, in conjunction with those of Varrault et al., 1994, suggest that various
regions of 5HT1aR’s ic2 loop are necessary to support coupling to G protein, but only the
mid-loop to C-terminal segment goes on to activate G protein. The critical role of the
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DRY sequence (at the very N-terminus of ic2) of the 5HT1aR (Kushwaha et al., 2006) in
stabilizing within loop and between loop interactions leading to receptor G protein
coupling is consistent with our conclusions. Further, these conclusions are supported by
the recent β2AR x-ray crystallographic data, and, indeed, seems to hold for the entire
superfamily in this almost universally conserved sequence. There is a very relevant
curiosity about β2AR, compared to rhodopsin involving the so called ion lock, of which
the DRY region of TM3/ic2 is involved. In the presence of inverse agonist carazolol, the
lock is broken in β2AR. Overall, the β2AR structure suggests less involvement of ic2 with
G protein activation; this observation coupled with the inverse agonism of β2AR are
likely important for 5HT1aR (which also shows inverse agonism) and the conclusions of
this dissertation. It certainly seems reasonable at this juncture to hypothesize that
5HT1aR’s structure is more open like BAR, compared to rhodopsin.
Thus, ic2’s N-terminus for several GPCRs is involved in receptor-G protein
coupling, and there is variability in whether the N-terminal ic2 loop supports G protein
activation. In early work with rhodopsin (Lembo et al., 1997; Bikker et al., 1998),
evidence supported the involvement of i2 in activation of G protein. In the alpha 2A
adrenergic receptor (Edwards and Limbird, 1999), ic2 does not activate the G protein, a
conclusion parallel to that reached in our investigations of H5HT1aR; both of these
receptors are coupled to Gi. It is certainly possible that functional attributes of ic2 have
evolved differentially across the super family of 7TMDR, especially regarding activation,
which can occur only after the necessary condition of coupling has been met.
With regard to ic3, β2AR utilizes the N- as well as the C-terminal regions to
couple to G protein; nevertheless, results clearly suggest that BAR’s ic3 C-terminus is
ideally designed to stimulate Gs without help (Munch et al, 1991). The recent
crystallographic structure for BAR finds an intact “toggle switch,”, originally seen in
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rhodopsin. It seems a small leap of inference to suggest that 5HT1aR has an intact toggle
since both β2AR and rhodopsin have it.
This trigger region affirms the significant role that ic3 has in G protein activation.
The ic3-C-terminus of alpha 2 adrenergic receptors plays a role in binding to Go’s
betagamma region. Our results with the H5HT1aR conclude that ic3’s N-terminal region
activates G protein, as does the C-terminal of ic3 (Varrault et al. 1994). Together, these
results may indicate that the entire ic3 loop is broadly involved across the receptor
family, but sub-segments of ic3 may be more or less important to individual types of
receptors as well as to the target signal transduction system (Turner et al., 2004).
Therefore, sub-segments of both ic2 and ic3 may have become more or less
important, especially regarding G protein activation and regulation, to individual types of
receptors as they have adapted to meet local needs. BAR’s relatively “open” crystal
structure compared to rhodopsin enables the cytoplasmic ends of TM segments and
attached ic loops to interact with a water cluster, ultimately leading to differential G
protein activation from a variety of conformations.
It is interesting to speculate that the entropic changes produced by peptide
introduction in our experiments may have something to do with this dynamic structural/G
protein activation relationship. BAR’s openness leads to structural flexibility and
instability, creating challenges for crytallographers. As the authors of the x-ray work
speculate (Kobilka, 2007; Kobilka and Deupi, 2007), final resolution of GPCR structures
beyond the stable rhodopsin may require crystals of the coupled receptor-G protein
complex. The many laboratories who have contributed biochemical approaches to
understanding 5HT1aR eagerly await such developments.
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APPENDIX A: CANNABINOIDS
Cannabis Introduction
The related natural products cannabis (Cannabis sativa) and hemp have many
biological components which have not been studied, with the exception of Δ9tetrahydrocannabinol (THC) and to a lesser extent cannabidiol (CBD). However, each
of these contain many other chemicals which have the potential to be bioactive. The
biological system which is the most perturbed by the introduction of these chemicals by
the ingestion of the natural products is the endogenous cannabinoid system. In humans
there are 2 known cannabinoid receptors CBD1 and CBD2 which are activated by the
endogenous ligand anandamide. These receptors are both G protein (Gi/o) coupled
receptors which affect adenylyl cyclase (negatively) and mitogen-activated protein kinase
(positively).
Hemp oil an essential oil, made from the leaves of cannabis, is a cocktail of many
oleagenous compounds called terpenes. Terpenes are secondary metabolites made up of
5 carbon isoprene units. These terpene compounds have been shown to possess
significant anti-inflammatory properties both in in vivo animal and ex vivo cell culture (de
las Heras et al., 2003) studies. Hemp oil does not contain any cannabinoids.
Figure 17: Isoprene
The isoprene is the basic
structural unit from which plants
synthesize terpenoids compounds.
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These natural products, cannabis and hemp, also contain compounds known as
cannabinoids. There are at least 66 cannabinoids that have been identified. THC is the
most widely known of these and is believed to be responsible for the psychoactive effects
of cannabis. However, another lesser studied compound, cannabidiol (CBD) is also
present and is not known to be psychoactive. CBD has shown potential for treating
anxiety disorders, seizure disorders, anti-psychotic (psychosis), and as a neuroprotective
agent (Zuardi et al., 1997; Carlini et al., 1981; Hampson et al., 1998; Jiang et al., 2005).
The serotonergic neurotransmitter system is affected by the hallucinogens such as
psilocybin and LSD (Aghajanian et al., 1975; Deliganis et al., 1991; Peroutka et al.,
1979). Therefore a preliminary investigation was undertaken to see if the psychoactive
effects of these constituents of cannabis and its relative hemp are mediated by the
serotonin receptors 5HT1aR and 5HT2aR.

Figure 18: Cannabidiol and
Serotonin
Structure of (-)-Cannabidiol
(CBD) and serotonin (5HT,
5-Hydroxy-Tryptamine)

The 5-HT1A receptor is found in the neural tissue of the central nervous system at
highest concentrations in the hippocampus, septum, frontal cortex, and dorsal raphe
nucleus. The receptor is negatively coupled to adenylyl cyclase, via Gαi which causes a
decrease in the amount of intracellular cAMP (Raymond et al., 1999).
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In addition to agonist binding studies for 5HT1aR, these studies were also done in
the 5HT2aR. The 5HT2a receptor is found in the cortex, caudate nucleus, nucleus
accumbens, hippocampus, and olfactory tubercule. It was identified as a serotonin
receptor subtype by its higher affinity for the ligand [3H]-spiperone, although its affinity
for 5HT is lower. The receptor is positively coupled to phospholipase C (PLC) system
via the g protein Gαq. The activation of PLC drives the hydrolysis of membrane lipids to
form diacylglycerol (DAG) and inositol triphosphate (IP3). The increased concentration
of IP3 causes the release of intracellular calcium (Ca++) from stores in the endoplasmic
recticulum. The increased concentration of DAG along with calcium activates protein
kinase C (PKC). The binding affinity assays for the constituents of cannabis and hemp
oil utilize the 5HT2aR antagonist [3H]-ketanserin (Barnes et al., 1999). These studies
examine if constituents of interest are able to displace an antagonist, rather than an
agonist as in the 5HT1aR studies.
Methods
Cell Culture: Chinese hamster ovarian (CHO) cells expressing the human 5HT1aR were
cultured in Ham’s F-12 medium fortified with 10% fetal calf serum and 200 µg/ml
geneticin in 75 or 175 cm2 flasks. Cultures were maintained at 37 °C in a humidified
atmosphere of 5% CO2. Cells were subcultured or assayed upon confluency (5–8 days).
CHO cells with cloned human 5HT1aR were kindly provided by Dr. John Raymond
(Medical University of South Carolina). NIH 3T3 cells expressing the rat 5-HT2aR were
cultured under similar conditions in DMEM fortified with 10% calf serum and 200 µg/ml
geneticin. These transfected cells were generously provided (Julius et al., 1990).by Dr.
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David Julius (UCSF). Both cell lines have been tested for mycoplasma with a PCR kit
(ATCC), and are free of contamination.
Receptor Preparation: Cells were harvested by the removal of culture medium followed
by the addition of a 0.25% trypsin solution. Upon the removal of the cell monolayer, an
equal volume of ice-cold culture medium was added to the cell-trypsin solution. The
resulting cell suspension was centrifuged at low speed (3000 rpm) in ice-cold medium for
10 minutes. The pellet was re-suspended in ice-cold Earle’s balanced salt solution
followed by centrifugation (3000 rpm) for 10 minutes. The cell pellet was re-suspended
in 10 ml of ice-cold binding buffer (50 mmol/l Tris, 4 mmol/l CaCl2, 10 µmol/l pargyline,
pH 7.4), homogenized with Teflon-glass homogenizer, and centrifuged at 450,000 g at 4
° C. to produce a crude membrane preparation, the pellet was re-suspended in 30 ml of
ice-cold binding buffer, and homogenized, first with Teflon-glass then with a Polytron
(setting 4) for 5 seconds. The receptor preparation was stored on ice and assayed within
the next 1.5 hour.
Assay of Receptor Activity
Binding of the agonist [3H]8-OH-DPAT ([3H]8-hydroxy-2-(di-npropylaminotetralin)) to H5HT1aR, or [3H]-ketanserin for 5HT2aR followed wellcharacterized in vitro protocols (Russo et al., 2005). Radioligands were purchased from
New England Nuclear (Boston, Mass., USA). The experimental 1 ml reaction mixtures,
in triplicate, were incubated for 30 minutes in a 30 °C water shaker bath. The
composition of the 1 ml reaction mixture was:
Experimental controls: 700 µl of receptor preparation; 100 µl of either binding buffer
(for total ligand binding) or 10 µM 5HT (final concentration for non-specific ligand
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binding), 100 µl of the tritiated agent (final concentration of 0.5 nmol/l [3H]8-OH-DPAT,
0.2 nM [3H]-ketanserin), and 100 µl of binding buffer in the case of controls.
5 ml of ice-cold Tris buffer, dried, and counted in 5 ml of Ecoscint (National
Diagnostics) liquid scintillation fluid in a Beckman LS 6500 instrument. Homogenates
were assayed for protein to maintain a nominal value of 50 µg protein per filter over
weekly assays. Total and non-specific binding tubes were run in triplicate.
Hemp oil versus [3H]-Ketanserin
Preliminary receptor binding experiments with dilutions of hemp oil were
performed with membrane preparations from cells transfected with the 5HT2aR. This
resulted in the binding curve below (Figure 19). The curve shows that hemp oil at a
dilution of 1/100 (2 on the graph) is able to decrease the amount of specifically bound
[3H]-Ketanserin to about 20% (as a percent of control). As the hemp oil concentration is
decreased there is a corresponding decrease in the amount of displacement of [3H]Ketanserin specifically bound to the receptor.

Figure 19: Ketanserin Displacement by
Hemp Oil at 5HT2a Receptor
Hemp oil vs. 5HT2aR. The 5HT2aR
antagonist [3H]-Ketanserin is displaced
by components of hemp oil in
membrane preparations of 5HT2aR.
All points are percent of control
(control=100%, no displacement). The
x-axis is the –log dilution of hemp oil.
3=1/1000, 5=1/100,000.
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Individual Components of hemp oil versus [3H]-Ketanserin
In an attempt to identify the individual terpene components of hemp oil which
may be responsible for the decrease in specifically bound [3H]-Ketanserin, individual
components of the oil were introduced to binding experiments using membrane
preparations from cells transfected with the 5HT2aR (Figure 20). The terpenes chosen
were: β-caryophyllene, 1,8-cineole, d-limonene, linalool, α-pinene, and α-terpinol. The
terpenes β-caryophyllene, linalool, and α-pinene were not able to decrease the binding of
[3H]-Ketanserin as compared to control. Small decreases in specific [3H]-Ketanserin
binding to 5HT2aR were seen with the terpenes 1,8-cineole (7%), d-limonene (10%), and
α-terpinol (18%).
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Figure 20: Terpene Components of Hemp Oil Effect on Ketanserin Binding
Ligand binding competition experiments in membrane preparations of rat
fibroblast cells expressing 5HT2aR. Individual terpene components of hemp
oil vs. 5HT2aR. The 5HT2aR antagonist [3H]-Ketanserin (0.2nM) is displaced
by the 1,8-cineole, d-limonene, and a-terpinol components of hemp oil.
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The terpinoid carvone was introduced into the binding assay with membrane
preparations from cells expressing 5HT2aR (Figure 21). Carvone at a concentration of
0.7 mM decreased the specific binding of [3H]-Ketanserin by 13% compared to control.
The combination of carvone with the terpene, terpineol decreased the effectiveness of
carvone alone only decreasing the specific binding of [3H]-Ketanserin by 5% compared
to control. Similarly, the combination of carvone with terpineol and limonene decreased
the effectiveness of carvone alone decreasing the specific binding of [3H]-Ketanserin by

Carvone+Terpin
eol+Limonene

Carvone (0.7
mM)

Carvone +
Terpineol

120
100
80
60
40
20
0

Control

% Specific [3H] ketanserin Bound

3% compared to control.

Figure 21: Terpene Effect on Ketanserin Binding
Ligand binding competition experiments in membrane preparations of rat
fibroblast cells expressing 5HT2aR. Carvone (0.7mM), Carvone+terpineol,
carvone+terpineol+limonene vs. 5HT2aR. The 5HT2aR antagonist [3H]Ketanserin (0.2 nM) is displaced by the Carvone.
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The dilution of the crude hemp oil mixture was able to displace specifically bound
ketanserin from 5HT2a. Our attempt to identify the individual components of hemp oil
responsible for this was only partially successful. We identified these components of
hemp oil which were weak displacers of ketanserin; 1,8-cineole (7%), d-limonene (10%),
α-terpinol (18%), and carvone (13%) (decreased specific binding). However our attempt
to identify the combinations of agents responsible for hemp oil’s activity only revealed
that the agents we chose were not synergistic in combination, but blunted the effect of
carvone alone.
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) versus [3H]-Ketanserin
The activity of CBD and THC at the 5HT2aR was assessed by their ability to
displace specifically bound [3H]-Ketanserin (Figure 22). THC was able to decrease the
amount of specifically bound [3H]-Ketanserin by 11% at a concentration of 32 uM. CBD
was able to decrease the amount of specifically bound [3H]-Ketanserin by 52% at 32 uM,
and 24% at a concentration of 16 uM. Methanol, which was included because it was used
in the initial dilutions of CBD and THC, had a very small effect on specific binding.
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Figure 22: Cannabidiol and THC Displacement of Bound Ketanserin
Displacement of specifically bound [3H]-Ketanserin (0.2 nM) at rat 5HT2aR
by CBD (1/100 = 32 uM; 1/200 = 16 uM) and THC (1/100 = 32 uM). MeOH
(methanol = 1%) was included as it was the initial diluent for CBD and THC.
All values are percent of control. N’s greater than 4 in samples assayed in
triplicate in multiple experiments (n=12).
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) versus [3H]8-OH-DPAT
The activity of CBD and THC in the 5HT1aR was assessed by their ability to
displace the ligand [3H]8-OH-DPAT (Figure 23). THC was not able to decrease the
specifically bound [3H]8-OH-DPAT when compared to control. Conversely CBD was
able to decrease the specifically bound [3H]8-OH-DPAT 90% at a concentration of 32
uM, 73% at a concentration of 16 uM, and 11% at a concentration of 8 uM. Because
CBD had a measured effect on decreasing bound 8-OH-DPAT, it could be acting at the
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ligand binding site. Therefore, it is warranted to investigate if CBD is also acting as an
agonist at 5HT1aR by examining G protein activation and second messenger regulation.
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Figure 23: Cannabidiol and THC Effect on 8-OH-DPAT Binding
Displacement of specifically bound [3H]8-OH-DPAT at H5HT1aR by CBD (1/100
= 32 uM; 1/200 = 16 uM; 1/400 = 8 uM) and THC (1/100 = 32 uM). N’s 4-6,
except 1/200 and 1/400 (1) in three separate experiments conducted in triplicate.
All values are percent of control.
p< 0.05 for Control vs. CBD (32) and Control vs. CBD (16)
Cannabidiol (CBD) Stimulated [35S]-γ-GTP Incorporation Into Gαi
Due to the lack of data to support the actions of THC as an agonist for 5HT1aR it
was not included in the [35S]-γ-GTP incorporation assays. CBD, which showed
considerable displacement of [3H]8-OH-DPAT in the binding assays, also activated Gαi
(Figure 24). The native ligand 5HT stimulated the incorporation of [35S]-γ-GTP into Gαi
at 10 uM to 157% of control. CBD stimulated the incorporation of [35S]-γ-GTP into Gαi
at 16 uM to 167% of control (*p<0.05, relative to control). The combination of 5HT and
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CBD showed an additive effect on the incorporation of [35S]-γ-GTP into Gαi to 223% of
control (**p<0.01, relative to control). These data indicate that CDB may be binding at
the ligand binding site of 5HT1aR and eliciting G protein activation thus, acting like an
agonist. To confirm that the G protein is being activated by CBD it is necessary to
measure its regulatory activity on adenylyl cyclase and its production of the second
messenger cAMP.
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Figure 24: Cannabidiol Effect on Incorporation of [ S]-γ-GTP into Gαi
These experiments were a measure of G protein activation. 5HT (10 uM)
and CBD (16 uM) stimulated incorporation of [35S]-γ-GTP into Gαi in cells
expressing 5HT1aR membrane preparations. CBD *p<0.05, relative to
control; 5HT/CBD **p<0.01, relative to control
Cannabidiol (CBD) Stimulated cAMP Production by Adenylyl Cyclase
Due to the lack of data to support the actions of THC as an agonist for 5HT1aR it
was not included in the cAMP assays. CBD was shown to act as an agonist at 5HT1aR
by the incorporation of [35S]-γ-GTP into Gαi. The next step in the signal transduction
cascade is to determine if activated Gαi is decreasing intracellular cAMP concentrations
by affecting adenylyl cyclase (Figure 25). The control in this experiment was the amount
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of FSK stimulated cAMP production. The native ligand 5HT was able to decrease
intracellular cAMP concentration to 28% of control. The combination of 5HT and NAN
(a 5HT1aR antagonist) decreased the effectiveness of 5HT alone to decrease FSK
stimulated cAMP production to 60% of control. CBD decreased FSK stimulated cAMP
production to 38% of control. The combination of 5HT and CBD had an additive effect
on the decrease in FSK stimulated cAMP production to 20% of control. The combination
of CBD with NAN also blunted its effect on FSK stimulated cAMP production to 76% of
control.
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Figure 25: Cannabidiol Effect on Intracellular cAMP Concentration
A measure of signal transduction properties of the agonist 5HT (1 uM), the
antagonist NAN-190(50 nM) , and the cannabinoid CBD (16 uM) at H5HT1aR.
These experiments were a measure of G protein regulation of its second
messenger. Inhibition of Forskolin (FSK)-Stimulated cAMP by Cannabidiol
(CBD), Serotonin (5-HT), and the inhibitor NAN-190 (NAN) in Whole Cells
Transfected With the Human 5-HT1a Receptor. All conditions contain FSK at 30
µM and the phosphodiesterse inhibitor isobutylmethylxanthine (IBMX) at 100
µM. Other concentrations in micromolar are: 5-HT (1); CBD (16); and NAN
(0.05). Results are expressed as percentage of FSK control as mean +/- S.E.M.
with n’s = 3-6. * p<0.05, relative to 5-HT; ** p<0.01, relative to CBD. Further
experimental details are found in Experimental Procedure.
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Cannabinoid Discussion
The examination of the individual agents contained in essential oil of hemp for
activity at the 5HT2aR has yielded information which may explain some of the diverse
effects of this natural product. The hemp oil cocktail itself showed much greater activity
at displacing [3H]-Ketanserin at the 5HT2aR, than any of its individual components
tested. This indicates that more of the components of hemp oil should be investigated as
the source of the ketanserin displacement. Small decreases in specifically bound [3H]Ketanserin were observed in the 5HT2aR receptor binding experiments with the
terpenoids 1,8-cineole (7%), d-limonene (10%), α-terpinol (18%), and carvone (13%). It
is not known if these compounds possess any agonistic properties in this receptor system.
However, because of their ability to slightly decrease the specific binding of the
antagonist ketanserin, these compounds may be modulating serotonergic
neurotransmission rather than acting as true agonists. The combination of the terpenoids
and carvone not having an additive affect on decreasing the specific binding of [3H]ketanserin more than the agents alone may indicate that they are competing for receptor
binding having an antagonistic effect on the binding of carvone.
The data for CBD and THC in the 5HT2aR and H5HT1aR has been previously
published in our lab (Russo et al., 2005). CBD was shown to decrease the specific
binding of [3H]-ketanserin and [3H]8-OH-DPAT, compared to control, although it is more
active in the 5HT1aR system. CBD clearly has agonistic properties at the 5HT1aR as
judged by its ability to stimulate the incorporation of [35S]-γ-GTP into Gαi, and decrease
FSK stimulated intracellular concentrations of cAMP via the negative regulation of AC.
The observation that the specific 5HT1aR binding site antagonist NAN is capable of
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blocking the agonistic effect of CBD is potentially significant. Since NAN blocks both
the action of established agonist 5HT and putative agonist CBD, these results support the
contention that CBD is acting at the receptor’s ligand binding site.
THC was shown to be very weakly active at displacement of [3H]-ketanserin at
the 5HT2aR, and had no measurable affect on the binding of [3H]8-OH-DPAT at
5HT1aR. Overall, the results with CBD provide evidence that cannabinoids have activity
in vitro beyond the expected interactions with cannabinoid receptors. If these results are
verified in vivo, we can speculate that future drug development studies may be impacted.
CBD itself, or modified versions might be utilized to treat maladies of serotonergic
dysfunction (depression, obsessive compulsive disorder, migraine headache) or be used
as adjunct treatment agents to boost the efficacy of current treatments.
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APPENDIX B: BACOPA
Bacopa monniera Introduction.
The natural product Bacopa monniera (BA) has a long history of herbal use in the
Indian Ayruvedic Medical System (Figure 26). More recently, the herbal use in western
medicine has been grounded in scientifically validated properties relevant to human
health. The focus of use in animal studies and human clinical trials has been the
beneficial properties in enhancing cognitive functions, especially memory processes, and
in the adaptogenic qualities of bacopa (Russo and Borrelli, 2005; Rai et al., 2003). These
properties have been particularly well studied with respect to cholinergic systems
relevant to cognition and neurodegenerative disease (Roodenrys et al., 2002). The
components of BA which are believed to be the active in biological systems are the
triterpene saponins bacopasides A & B.
Other neurotransmitter systems of interest, such as the serotonergic may be
relevant to bacopa’s pharmacology. Reports of relevance of the role of serotonin in
modulation of cognition involve the use of (S)-WAY 100135, a 5-HT1aR antagonist, to
counteract the impairment of spatial learning in rats due to intra-hippocampal
administration of the cholinergic antagonist scopolamine (Carli et al., 1995). Serotonin
depletion in the prefrontal cortex was also shown to cause cognitive inflexibility in
primates (Clarke et al., 2004). Thus, an investigation of the specific serotonergic
properties of BA is warranted. These studies utilized extracts of bacopa, supplied by
Geni Herbs (Nobelsville, IN), to examine if it has any activity at the human 5HT1aR and
the rat 5HT2aR.
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Bacopa Dilution for Experiments
Bacopa fractions were re-dissolved in 0.4 mL of absolute ethanol. This was then
diluted 1/10 in distilled water. Further dilutions were in distilled water 1/10 for a total
dilution of 1/100. This approach was based upon preliminary experiments [3H]
Ketanserin binding at the rat 5HT2aR (Figure 27).

Fig. 26: Bacopa monniera (Brahmi)
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Bacopa Extract Affect on the specific binding of [3H]8-OH-DPAT at H5HT1aR and
[3H]-Ketanserin at rat 5HT2aR.
Ligand binding experiments were completed for five dilutions of an extract of
Bacopa monniera. All of the BA dilutions tested were able to displace [3H]8-OH-DPAT
from its binding site at the 5HT1aR (Figure 28). The best results were observed with the
smallest dilutions (1/100 and 1/4000), which decreased the specific binding of [3H]8-OHDPAT to 37±5% and 33±9% as a percent of control respectively. Thus about a 60%
reduction in agonist binding was achieved at these concentrations. The 3 higher dilutions
showed some displacement activity however, the agonist displacement observed was less

% Specific [3H]-Ketanserin Bound

and more variable at these concentrations.
120
100
80
60
40
20
0
Control

EtOH

H20 Ext.

EtOH Ext.

Treatment

Fig. 27. A comparison of bacopa extracted in water versus ethanol. Specific binding of
[3H]-Ketanserin in membranes containing the rat 5HT2a receptor was measured. Extracts
were diluted 1/100 prior to assay. Ethanol alone did not influence binding. Values are
mean +/- S.E.M. with n's = 4-6.
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A parallel set of experiments to those summarized in Figure 28 with H5HT1aR
were conducted with [3H]-Ketanserin in rat 5HT2aR (Figure 29). At the 1/100 dilution,
BA's ability to displace ligand is about the same at 5HT2aR (about 66%) as at H5HT1aR
(about 63%). At 1/600 dilution, BA displaces only about 25% of [3H]-Ketanserin (Figure
29). This compares with a 1/4000 dilution of BA at the H5HT1aR where about 67% of
[3H]8-OH-DPAT is displaced (Figure 28). A 1/4000 dilution of BA displaces only 17%
of [3H]-Ketanserin at rat 5HT2aR (Figure 29). The overall conclusion is that while BA is
active at both receptors, it has greater binding potential at H5HT1aR compared to rat
5HT2aR.
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Figure 28: Effect of Bacopa Extracts on Specific Binding of 8-OH-DPAT
Binding of bacopa at human 5HT1aR. Five dilutions of the extract in ethanol were
tested for ability to displace specifically bound [3H]8-OH-DPAT. All values are
percent of control ± SEM; n’s 4-5. p< 0.05 for Control vs. BA (1/4000) and
Control vs. BA (1/100)
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Figure 29: Effect of Bacopa extracts on Specific Binding of Ketanserin Binding at rat
5HT2aR. Five dilutions of the extract in ethanol were tested for their ability to displace
specifically bound [3H]-Ketanserin. All values are percent control +/- SEM; n’s 4-5.
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Figure 30: Bacopa Effect on Intracellular cAMP Concentration
cAMP experiments were a secondary measure of G protein activation. Bacopa
(BA; 1/200) was tested for its ability to effect cAMP levels in vitro all
conditions include FSK and IBMX. Bacopa significantly decreased
intracellular cAMP levels after pre-treatment with forskolin (FSK). NAN is a
5HT1aR antagonist. All values are pmol cAMP ± SEM, n’s 3-9.
* p<0.01 5HT vs. 5HT/NAN
** p<0.01 BA vs. BA/NAN
Bacopa Extract Affect on Intracellular cAMP Concentration
Bacopa was shown to displace agonist at 5HT1aR. The incorporation of [35S]-γGTP into Gαi was not measured in these experiments for this bacopa extract. However,
its agonistic activity was demonstrated in cAMP experiments, with bacopa activated Gαi
decreasing intracellular cAMP concentrations by affecting adenylyl cyclase. The control
in this experiment is the amount of FSK stimulated cAMP production by adenylyl
cyclase (AC) (Figure 28). The native ligand 5HT was able to decrease intracellular
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cAMP concentration to 1.9±0.1 pmol compared to 15±0.6 pmol for control. NAN alone
demonstrated a decrease in cAMP concentration to 12±0.7 pmol. The combination of
5HT and NAN (a 5HT1aR antagonist) decreased the effectiveness of 5HT alone to
decrease FSK stimulated cAMP production to 4.5±0.1 pmol. BA decreased FSK
stimulated cAMP production to 7.2±0.5 pmol. The combination of BA with NAN also
blunted its effect on FSK stimulated cAMP production to 10±0.3 pmol. The reductions
in cAMP concentration were statistically significant for 5HT vs. 5HT/NAN (p<0.01) and
BA vs. BA/NAN (p<0.01). These data along with the binding displacement data for 8OH-DPAT demonstrate a role for constituents present in bacopa as 5HT1aR agonists.
Signal transduction activity of BA was not measured at rat 5HT2aR.
Bacopa monniera Discussion
The extracts of the natural product Bacopa monniera tested in these experiments
**
for signal transduction activity in the human 5HT1aR have shown that constituents of
bacopa have agonistic properties in this neurotransmitter system. The majority of the
extracts tested significantly displaced specifically bound agonist [3H]8-OH-DPAT. The
*
most active extract displaced about 60% of the ligand. The agonistic properties of
bacopa were demonstrated by the activation of the 5HT1aR coupling protein Gi by
testing the signal transduction system via its target second messenger, causing a
significant decrease in the FSK stimulated intracellular concentration of cAMP. This is
an indication that the bacopa activated Gαi is negatively regulating adenylyl cyclase and
decreasing its production of cAMP. Thus, it has been demonstrated that components
present in the extracts of the natural product Bacopa monniera are able to bind to the
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5HT1aR, activate Gαi, and affect the second messenger system in a similar manner to
5HT.
These extracts do not demonstrate equipotent activity to the ligand 5HT.
However, further purification and identification of the individual components in the
fractions may elucidate the source of bacopa’s serotonergic activity. Currently, such
studies are being conducted. It will also be of interest to further pursue characterization at
the 5HT2aR to clarify whether BA is agonistic or antagonistic. These studies have yet to
be conducted. Interest in bacopa, both in terms of its effects in the nervous system and
other tissues as well as its clinical efficacy is increasing world wide. Additional studies,
both in the serotonergic system and with other neurotransmitters and in the applied realm
are well worth pursuing.
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APPENDIX C: CELL VOLUME
Serotonin (5HT) has many actions on neuronal function in its role as a
neurotransmitter. However, its actions go far beyond neurophysiology, branching into
very basic cellular processes such as osmotic homeostasis (Azmitia et al., 2001; Simard
et al., 2004). Additionally, 5HT’s actions are not limited to neurons; many other cell
types are involved, including mast cells, cells of the gastrointestinal tract, and
significantly for the nervous system, glial cells (Ramos et al., 2004). Of the seven known
classes of 5HTR, only one, the 5HT3R’s are membrane ion channels. The remainder of
the 5HT receptor family are G protein-coupled (GPC), seven transmembrane domain
(7TMD) receptors. G protein-coupled 7TMD receptors are the target for many
neurotransmitter, hormone, and autacoid ligands whose structures, binding properties,
and signal transduction characteristics are under active investigation.
A prominent member of the GPC 5HTR’s is the 5HT1aR, which has been
associated not only with vital neurological and psychological processes (depression,
obsessive compulsive disorder), but also with astroglial physiology (Ramos et al., 2004)
and a Na+/H+ exchanger (Garnovskaya et al., 1997). We have previously conducted a
series of studies with H5HT1aR, including investigations at the receptor/G protein
interface and with small binding ligands, such as cannabidiol (Russo et al., 2005) and
DPT (Thiagaraj et al., 2005). The work presented here represents preliminary studies
conducted with primary astroglia from rats (Jayakumar et al., 2006), a monkey kidney
(MCK) cell line, transfected CHO cells expressing 5HT1aR, rat fibroblasts (3T3)
expressing 5HT2aR, and wild type CHO cells. These studies used the 5HT ligands
quipazine, buspirone, 8-OH-DPAT, ketanserin, ondansetron, and carbamidotryptamine...
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Astrocytes perform many vital activities in the central nervous system:
glutathione synthesis, neurotransmitter uptake and metabolism, allowing neurons to
continue functioning properly. Toxins such as ammonia, which can cause cell swelling,
can compromise the proper function of astrocytes (Simard et al., 2003). Finding a
therapeutic agent to reduce that swelling could be useful in treating hepatic
encephalopathy. These preliminary studies focus on the relationship between 5HT and
astroglial function with some comparisons to other cell types.
Methods
Cell Culture: Chinese Hamster Ovary (CHO) cells expressing the H5HT1aR (S27- ATCC
designation) were cultured in Ham’s F-12 medium (GIBCO) fortified with 10% fetal
bovine serum (FBS) and 200 ug/ml geneticin. Cultures were maintained at 37°C in a
humidified atmosphere of 5% CO2. Cells were sub-cultured or assayed upon confluency
(5-8 days). Cell lines have been tested for mycoplasma with a PCR kit (ATCC), and are
free of contamination. Cloned H5HT1aR was kindly provided by Dr. John Raymond.
NIH 3T3 (ATCC designation) cells expressing the rat 5HT2aR were cultured under
similar conditions in DMEM fortified with 10% calf serum (CS) and 200 ug/ml geneticin.
These transfected cells (Julius et al., 1990) were kindly provided by Dr. David Julius
(UCSF). Non-transfected cell lines were obtained from the American Type Culture
Collection (ATCC); Wild type (WT) CHO cells (CHO-K1; CCL 61); and Rhesus
monkey kidney cells (MKC) (LLC-MK2; CCL 7). These cells were cultured in the
following media: WT CHO, S 27 medium minus geneticin; MKC, DMEM + 10% cosmic
CS.
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Primary rat astrocytes were prepared as described by Rama Rao et al. (2003).
Cells were dissociated from the cerebral cortex of neonatal rats in serum-fortified
DMEM. After two weeks, the cultures of 95% (+) astrocytes were differentiated with
dibutyryl cAMP. Cells were typically used for functional and receptor binding activity
after about one total month in culture.
Treatment Protocols for Functional (Cell Volume) Experiments: In the case of primary
astroglial cultures, old medium was removed, and fresh medium containing test drugs
(e.g. buspirone (500 nM); NAN-190 (50 nM); quipazine (500 nM)), was added. 18 hours
later, the cells were assayed by the OMG cell volume method (see below). In the case of
serial cultures, cells were harvested in 0.25% trypsin (in phosphate-buffered saline),
counted and plated in 6-well plates and cultured to near confluency. At this point, old
culture medium was removed, and new medium containing drugs was added as described
above.
O-Methyl-Glucose (OMG) Assay (Functional Cell Volume Assay): Following the 18
hours incubation with drugs, [3H]-O-methyl-glucose (OMG) was added to a final
concentration of 200 mM, and the cultures were returned to the incubator. 24 hours later,
old culture medium was collected and saved for determination of extra-cellular OMG
concentration. Cells were then rinsed three times in the following ice-cold buffer: 10
mM Tris; 290 mM sucrose; 0.5 mM calcium nitrate; 10 mM phloretin.
0.5 ml of 1 N NaOH was added to each well, to lyse the cells, and the cultures
were incubated at 37°C for 2 hours. Cells were scraped, removed, and aliquots were
saved for protein determination and OMG assay. Protein determinations used a
colorimetric Coomasie blue assay (Bradford, 1976). 0.25 mL of the cellular homogenate
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were mixed with 0.1 ml of formic acid to neutralize the NaOH and counted in Ecoscint
scintillation fluid (National Diagnostics, Atlanta) for determination of intracellular OMG.
0.1 mL of the culture medium was also added to Ecoscint and counted by liquid
scintillation for determination of extra-cellular OMG. OMG results are expressed as the
ratio of intracellular to extra-cellular concentrations. For most assays, conditions were
run in triplicate or quadruplicate.
5HT Agents and Cell Volume
These experiments were undertaken to explore the following question: Can 5HT
agonists and antagonists alter cultured rat astrocyte physiology as measured by a
functional cell volume determination. Cell volume was measured using the [3H]-OMG
method described above. Glucose uptake reflects cell volume as it is not only necessary
as a source of energy but also acts as an osmotic agent to keep extracellular and
intracellular spaces iso-osmolar. Following an 18-hour treatment with quizapine the
extracellular and intracellular amounts of [3H]-methyl-glucose were determined. The
ligand quipazine, is not highly specific, affecting both 5HT2aR and 5HT3R. 500 nM
quipazine (Figure 31) resulted in a significant reduction in cell volume in rat primary
astrocyte cultures versus control, 85.9±2.6% vs. 100±3.1% (p< 0.02). In parallel
experiments in rat astrocyte cultures, the 5HT1aR partial agonist, buspirone, also
modestly reduced cell volume; the 5HT1a antagonist, NAN-190 blocked this effect (data
not shown). Functional assays with 5HT2aR agents in these exploratory experiments
were inconclusive. These functional pharmacology experiments gave provisional
evidence that cultures of rat astrocytes contain multiple sub-types of 5HT receptors.
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Effect of Quipazine on Cell Volume in Primary
Rat Astrocytes
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Figure 31: Serotonergic Effect on Cell Volume of Primary Astrocytes
The effect of 5HT 2/3R ligand quipazine on the cell volume in rat primary
astrocyte cultures. Changes in cell volume were assessed by the uptake of
[3H]-OMG in astrocytes treated with quipazine and astrocytes not treated as
control. Treatment with quipazine resulted in a significant reduction in cell
volume versus control 85.9±2.6% vs. 100±3.1% (p< 0.02)
Determination of 5HTR Expression in Primary Rat Astrocytes
Although there have been a number of efforts to characterize 5HTR expression
for astrocytes in the in vivo setting, little has been done to study these receptors in
primary cell culture of rat astrocytes. This is problematic because the cell culture setting
provides a significant model for evaluating serotonin’s functional physiology and
pharmacology. To begin the process of characterizing serotonin receptors in primary rat
astrocytes, we exposed cultures to varying concentrations of [3H]-5HT using an
experimental design parallel to that used for the [3H]-8-OH-DPAT experiments that
comprise the bulk of this dissertation.
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Membrane preparations of these astrocytes yielded data for specific [3H]-5HT
binding that can be divided into two major components when the experiments are
conducted in the presence or absence of cold 8-OH-DPAT. Figure 32, represented in
double-reciprocal format, shows these two components as DPAT-dependent or
independent binding. The DPAT-dependent binding comprises only about 5% of total
[3H]-5HT binding. This component can also be called the high affinity component of
binding as the Kd for [3H]-5HT is in the low nanomolar range (about 1.4 nM).
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Figure 32: Serotonin Receptor Population of Primary Rat Astrocytes
Ligand binding assay of [3H]-5HT in primary rat astrocytes. The
upper line (square shape) is the 8-OH-DPAT dependent line (for
receptors 5HT1a and 5HT7). The lower line (diamond shape)
represents 8-OH-DPAT independent binding.
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In additional preliminary investigations, we designed experiments to further subdivide the high and low affinity components of [3H]-5HT binding. Even though 8-OHDPAT is typically described as specific for the 5HT1aR, like any drug, it is imperfectly
discrete. It also has activity at the 5HT7R. The agent carbamidotryptamine is reasonably
selective for the 5HT7R compared to 5HT1aR. Thus, if experiments are conducted with
the high affinity, 8-OH-DPAT-dependent component of [3H]-5HT binding either in the
presence or absence of carbamidotryptamine, an estimate of the ratio of 5HT1aR/5HT7R
presence can be made. These experiments were conducted, with the following result:
approximately 20% of the high affinity binding is due to 5HT1aR and about 70% is
contributed by the 5HT7R (data not shown); another 10% is either in the realm of
experimental error or to some other, unknown high affinity receptor.
Recall that only 5% of total [3H]-5HT binding is in the high affinity realm; thus,
95% of the binding is lower affinity. What had been previously known about primary
cultured rat astrocytes was that the 5HT2aR is expressed in these cells (Deecher et al.,
1993). Our preliminary studies with quipazine in the cell volume functional assay fit this
observation, but quipazine also is not completely specific. It has been demonstrated to
possess both 5HT2aR and 5HT3R activity. Thus, we hypothesized that the low affinity
binding component in these cells could also have a 5HT3R component. To test this
hypothesis, we conducted two sets of low affinity (high [3H] 5-HT conc.) experiments,
one in the presence of ketanserin, a modestly specific 5HT2a antagonist, and one in the
presence of ondansetron, a fairly specific 5HT3R antagonist. The preliminary results
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suggest that about 30% of the low affinity binding is due to the 5HT3R and about 70% is
represented by the 5HT2aR (data not shown).
These early experiments suggest that primary cultured rat astrocytes express four
different serotonin receptors: 5HT1a, 5HT7, 5HT2a, and 5HT3. The initial nature of
these results must be verified by additional repetition of the experiments and direct
testing for the various receptor sub-types by using labeled specific analogues such as
[3H]-8-OH-DPAT, [3H]-odansetron, etc. These exciting experiments, however, are
beyond the temporal scope of this dissertation project. The expression of these receptor
subtypes can be confirmed by RTPCR, which measures translation of genes to mRNA.
However, this does not guarantee expression of the protein of interest.
Determination of 5HT1aR Expression in MKC Cells
We wanted to test specificity of the 5HT effect on cell volume (especially
regarding 5HT1aR) by conducting additional experiments in cells known to express or
not express 5HTR. There have been no published reports of the 5HT1aR being expressed
in MKC cells. To determine if the receptor is present, we employed ligand binding
experiments with the 5HT1aR ligand [3H]-8-OH-DPAT. In membrane preparations of
MKC, a concentration dependent increase in specific binding of [3H]-8-OH-DPAT was
observed versus control (Figure 33). To determine if the receptor is actually expressed
and our data is not an artifact, RTPCR and specific antibodies for the 5HT1aR can be
utilized in future studies.
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Figure 33: MKC 5HT1a Receptor Binding
A binding assay with the radiolabled 5HT1aR ligand [3H]-8-OH-DPAT
shows a concentration dependent (x-axis) increase in specific binding,
suggesting that the MKCs do indeed express the 5HT1aR. Specific binding
is total minus non-specific (NS) binding of triplicates. NS binding is
conducted in the presence of 10 µM 5HT.
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Buspirone Affect on MKC volume
The addition of 500 nM buspirone to MKC followed by [3H]-OMG incubation
showed a small decrease in cell volume as a percent of control (Figure 34). The change
in cell volume was 94±4% for buspirone treated cells versus 100±5% for control. While
not significant, this effect hints that a similar result to that seen in the primary rat
astrocytes could occur upon optimization of experimental conditions. To further test the
hypothesis that 5HT1aR agonists like buspirone, reduce cell volume in cells containing
5HT1aR, but not in cells lacking the receptor, we conducted experiments in the CHO
cells containing cloned H5HT1aR. Buspirone reduced cell volume by 7% (data not
shown). The volume reduction effect is blocked by the 5HT1aR specific antagonist
NAN-190 (data not shown). While this effect is small, it should be noted that this activity
occurs in cells that have not been challenged. It is anticipated that cells challenged with
an agent causing cell swelling (like ammonia) will show a larger response to 5HT1aR
agonists. Additional experiments were run in wild type CHO cells (that do not express
5HT1aR) and in 3T3 fibroblasts that express 5HT2aR. Buspirone had no effect on cell
volume in these cells (data not shown).
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Figure 34: Buspirone Effect on MCK Cell Volume
500 nM Buspirone was able to reduce the cell volume of monkey
kidney cells relative to control. Cell volume was assessed by
cellular uptake of [3H]-OMG by MKC cells. MKCs have not been
reported to express the 5HT1aR. 94±4% for buspirone treated cells
versus 100±5% for control.
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Cell Volume Discussion
It is noteworthy that the MKC cell line has a nearly identical response to
buspirone as the CHO line transfected with H5HT1aR and the cultured rat primary
astrocytes; the results presented here are, to the best of our knowledge, the first
demonstration of 5HT1aR agonist binding and effect in this cell line and in the primary
astrocyte cultures. The effect of the 5HT1a partial agonist buspirone seems to be specific
as cells that either do not express 5HT1aR or express some other 5HTR are unresponsive
to the agent.
These initial studies set the stage for further work examining the mechanisms of
5HT1aR-linked changes in cell volume. Of particular interest will be development of a
cell damage model, expansion of dose-responsiveness and ligand specificities, and
extension of the work into coupling of the receptor activation to signal transduction
networks. It should be pointed out though, that cell volume regulation in rat astrocyte
culture does not seem to be a function of 5HT1aR alone. Since the cultured astrocytes
also express 5HT7R, 5HT2aR, and 5HT3R, and at the very least, 5HT3R seems to be
functional (quipazine reduction of cell volume; Figure 31), 5HT regulation of cell volume
needs to be explored in the context of multiple 5HTR. These initial investigations
promise a series of potentially meaningful projects in the future.
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Figure 35: Intracellular Loop 2 (ic2) of 5HT1aR
A pictographic representation of the 17 amino acid second intracellular
loop 2 of the 5HT1aR. The first amino acid shown in transmembrane
domain 3 (TM 3) I is the first amino acid residue in the peptide mimic
P11. The last amino acid reside shown in transmembrane domain 4 (TM
4) R is the final amino acid residue in ic2 peptide mimic P27.
Compound

P11
P21
P22
P23
P24
P25
P26
P27

Sequence

IALDRYWAITD
LDRYWAITDP
RYWAITDPID
WAITDPIDYV
ITDPIDYVNK
DPIDYVNKRT
IDYVNKRTPR
YVNKRTPRPR
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